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Errata – p.2 
The following is a correction for page 60: Figure 21 B-D color coding is corrected to match 
the legend.  
 Errata – p.3 
The following correction is to line 23 of page 65 
Using microgels labeled with a near IR dye, DyLight 650, loaded with representative Blue 
(350/440) 100 nm Fluorosphere nanoparticles… 
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SUMMARY 
Pulmonary drug delivery is a non-invasive method for targeted delivery of 
therapeutics for the treatment of respiratory diseases such as asthma, idiopathic pulmonary 
fibrosis, or cystic fibrosis. Although the lung appears to be an “easy” target for site-specific 
delivery, there are several physiologic barriers hindering its effectiveness. For particle 
deposition in respiratory airways, the aerodynamic diameter of particles should fall 
between 0.5-5 µm, however, alveolar macrophages rapidly clear particles within this 
geometric range. Additionally, nano-scale particles are required for efficient transport 
through the pulmonary mucosa and to facilitate efficient endocytosis for intracellularly 
targeting therapeutics. These design parameters suggest a two-stage system is necessary 
for efficient therapeutic delivery; a microparticle for aerodynamic properties and a 
nanoparticle for drug delivery.  
A nanoparticle-inside-microgel multi-stage formulation could provide efficient, 
intracellular delivery of nanoparticles to target cells of interest. The microgel carriers are 
designed for (a) protease-triggered release of drug loaded nanoparticles, (b) avoiding rapid 
clearance by alveolar macrophages, and (c) appropriate aerodynamic properties, while the 
nanoparticles are designed to (a) carry small hydrophobic molecules. The overall objective 
is to test this delivery system by investigating (i) how the microgels and nanoparticles 
interact with the phagocytic immune cells in vitro (Aim 1) and in vivo (Aim 2) and (ii) how 
we can recapitulate the vascular pulmonary environment to study these interactions in an 




CHAPTER 1. INTRODUCTION 
1.1 Overview 
Asthma, chronic obstructive pulmonary disorder (COPD), and cystic fibrosis (CF) 
are chronic inflammatory diseases characterized by an influx of innate immune cells to the 
lungs, including macrophages [1–3], neutrophils [3–5], and eosinophils [2,3,6,7]. These 
cells impose a heavy enzymatic burden through proteases such as matrix 
metalloproteinases and elastase that ultimately promote significant tissue damage. 
Pulmonary delivery is a potentially non-invasive administration route for treating these 
diseases; however, the anatomy and physiology of the lung present several design 
challenges for achieving efficient and effective drug delivery. Nanoparticles can inherently 
provide protection for encapsulated biologic therapeutics (proteins, RNAs) from high 
levels of exogenous proteases present in lung diseases, but they must be smaller than 300 
nm to provide efficient cellular endocytosis [8–11] and transport across the mucosal barrier 
to target epithelial cells [12–14]. However, nanoparticles alone cannot efficiently 
aerosolize and deposit within the lung via inhalation; particles with aerodynamic diameters 
less than 1 µm are predominantly exhaled, and greater than 5 µm are impacted in the mouth 
or throat [15]. While those between 1-5 µm are deposited more efficiently into the deep 
lung, alveolar macrophages rapidly phagocytose particles with geometric diameters within 
the 1-5 µm range [16,17], making efficient delivery difficult. 
Additionally, pre-screening therapies for diseases such as idiopathic pulmonary 
fibrosis (iPF) and CF are further complicated by the lack of accessible representative 
animal models. iPF’s cause and pathogenesis are poorly understood, but the hallmark 
fibroblastic foci and irreversible scarring lead to severe pulmonary damage [18]. Mouse 
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models often used to “mimic” iPF use small molecules (e.g. bleomycin) to induced lung 
damage and scarring rather than underlying physiology [19]. CF is a relatively well 
understood etiology caused by mutations to the cystic fibrosis transmembrane conductance 
regulator (CFTR). However, CFTR knockout and mutant mice lack the severe human lung 
pathology and do not replicate the lower airway extracellular barriers present in human CF 
diseases [20,21]—preventing the study of particle or drug transport in relevant models.  
Thus, this thesis addresses pulmonary delivery with a multi-stage particle 
nanoparticle-inside-microgel and develops an in vitro human microphysiologic model. 
1.2 Hypothesis 
The central hypothesis is that a nanoparticle-inside-microgel (Nano-in-Micro) 
multi-stage formulation could provide efficient, intracellular delivery of nanoparticles to 
target cells of interest. The overall objective is to test this delivery system by investigating 
(i) how the microgels and nanoparticles interact with the phagocytic immune cells in vitro 
(Aim 1) and in vivo (Aim 2) and (ii) how we can recapitulate the vascular pulmonary 
environment to study these interactions in an in vitro setting (Aim 3). 
1.3 Specific Aims 
 Aim 1: Nano-in-Micro in vitro Characterization 
The overall goal of this aim was to characterize the multi-stage delivery system in 
vitro. A maleimide-thiol based Michael Addition During water-in-oil Emulsion (MADE) 
method was used to fabricate the Nano-in-Microgels. The working hypothesis was that the 
size and elastic properties of the microgel could help reduce the rapid clearance by 
macrophages to prolong microgel presence in the lung from minutes to hours.  
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A. Nano-in-Micro particles were fabricated with two peptide crosslinkers, a CGRGGC 
(trypsin-responsive) or a CGAAPVRGGGGC (elastase-responsive) peptide were 
incorporated into the microgels; the initial macromer concentration (20-50% w/v) 
was varied to determine the effects on size distribution, degradation rate, and in 
vitro macrophage phagocytosis.  
B. Nanoparticles for targeting neutrophilic (PMN) inflammation were fabricated and 
characterized. Fibrosis Relevant drugs (R)-Roscovitine, Nexinhib-20, and 
Tanshinone IIA were incorporated into PLGA nanoparticles and loaded into 
elastase-responsive Nano-in-Microgels. PLGA encapsulation, microgel 
degradation, and in vitro PMN uptake were measured. 
 Aim 2: Nano-in-Micro in vivo Characterization 
The overall goal of this aim was to characterize the multi-stage delivery system in 
vivo. Naïve mice were used to characterize the impact of the microgel formulation on 
phagocytosis and clearance, while an acute neutrophilic inflammation model was used to 
test the efficacy of the system in targeting neutrophils. 
A. Nano-in-Micro trypsin- and elastase- responsive particles were delivered to naïve 
mice to characterize the biodistribution, phagocytosis, and clearance. 
B. Nano-in-Micro loaded with fluorescent reporter nanoparticles and therapeutic 
PLGA nanoparticles were used in an LPS induced acute neutrophilic inflammation 





 Aim 3: Development of a vascularized lung-on-a-chip 
The purpose of this aim was to develop a microphysiologic device that replicates 
three key features of the respiratory airways (1) primary human lung epithelial cells at an 
air-liquid interface (2) interstitial space for healthy or diseased fibroblasts and (3) a network 
of perfusable blood vessels to recapitulate both healthy and fibrotic pulmonary 
environments. 
1.4  Outline 
This work focuses on the design of protease-responsive biomaterials for site 
specific delivery to lung diseases. Background information on pulmonary drug delivery 
design challenges, biomaterials used throughout this thesis, and current pulmonary testing 
models can be found in Chapter 2. In Chapter 3 we investigate how perturbations of the 
starting polymer concentration during the fabrication of both a trypsin- and elastase-
responsive Nano-in-Micro system effects the size and in vitro macrophage phagocytosis. 
Additionally, we encapsulated small molecule drugs that appear promising for fibrosis into 
water-soluble PLGA nanoparticles. We then encapsulated these drug-loaded PLGA 
nanoparticles into the elastase-responsive microgel formulation. In Chapter 4, to 
understand how the Nano-in-Micro system interacts with the innate immune phagocytes, 
we investigated the biodistribution, phagocytosis and clearance of the microgels in naïve 
mice. We then investigated the use of fluorescent and drug-loaded elastase-responsive 
Nano-in-Micro particles to deliver therapeutic cargo to neutrophils in an LPS acute 
neutrophilic inflammation model. While there are numerous mouse models that use small 
molecules to create acute and chronic pulmonary inflammation, due to the poor ability of 
mouse models to mimic human pulmonary diseases, in Chapter 5, we designed and 
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fabricated a microphysiologic device to incorporate microvasculature surrounded by 
healthy or diseased fibroblasts underneath a thin film membrane that supported lung 
epithelial cells and their differentiation at an air-liquid interface. The schematic overview 
of these aims is detailed in Figure 1.  
Figure 1: Schematic Overview of Aims 
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CHAPTER 2. BACKGROUND 
 Treating Pulmonary Disorders 
While traditional systemic drug delivery through oral or injection routes is 
convenient and widely used, it is inefficient and the optimal therapeutic dose is often 
missed. Too low of a concentration renders the therapy ineffective, and too high of a 
concentration can lead to off-target toxicity. Site-specific delivery can reduce the off-target 
toxicity of therapeutics while also delivering a relevant dose to the specified tissue. 
Noncommunicable diseases are responsible for 70% of deaths worldwide, with chronic 
respiratory diseases accounting for the third highest global mortality rate [22]. Inhalation 
therapy has the potential to be the optimal mode of delivery for respiratory diseases such 
as asthma, chronic obstructive pulmonary disorder (COPD), idiopathic pulmonary fibrosis 
(iPF), and cystic fibrosis (CF). Inhaled therapeutics such as corticosteroids are common 
and have proven beneficial in controlling and maintenance of asthma and COPD [23–29]. 
However many pulmonary therapeutics are still delivered orally; iPF has two available 
therapeutics, Pirfenidone and Nintedanib, that are delivered orally and while tolerable, 
cause adverse side effects such as nausea, abdominal discomfort, and fatigue [29–36]. 
Pulmonary delivery is a potentially non-invasive administration route for both systemic 
delivery of therapeutics and site-specific targeting therapies. Although lung delivery 
appears to be an easy target for non-invasive administration of both systemic delivery of 
therapeutics and site-specific targeting therapies, the lung has several physiologic barriers 




 Design Challenges in Pulmonary Drug Delivery 
The lung branches from large to small conducting airways down to smaller 
respiratory bronchioles and alveoli. The larger airways are characterized by ciliated 
pseudostratified columnar epithelium and goblet cells which, as the airways branch, 
transition into a simple ciliated cuboidal epithelium with club cells and eventually branch 
into squamous epithelium of the alveoli which are a mixture of type I and II epithelium and 
an abundance of alveolar macrophages (schematic in Figure 2). The high surface area of 
the respiratory airways and thin barrier that allows for efficient gas exchange between the 
respiratory epithelium and vascular endothelium also allows for efficient drug absorption 
into systemic circulation. For diseases such as idiopathic pulmonary fibrosis (iPF), chronic 
obstructive pulmonary disorder (COPD), asthma, tuberculosis and lung cancers, 
pulmonary delivery offers site-specific targeting of drugs while lowering off-target 
therapeutic side effects.  
Figure 2: Lung Schematic 
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2.1.2.1 Pulmonary Particle Deposition 
The anatomy and physiology of the lung present several design challenges for 
achieving efficient and effective drug delivery. The deposition of particles in the lungs is 
primarily dependent on particle size and shape [37–39]. Considering size, the mechanism 
for particle deposition is inertial impaction, sedimentation, and diffusion. For small 
particles (< 0.5 µm), diffusion is dependent on Brownian motion and can be described by 
Stokes-Einstein, while sedimentation relies on gravity and time for particles to settle and 
can be influenced by breath-holding. Larger particles often deposit by inertial impaction as 
the particle’s momentum allows the particle to maintain trajectory as air flow changes 
directions as the airways branch. Generally, the anatomical structure of the lung dictates 
particles with an aerodynamic diameter less than 0.5 µm will be exhaled, between 0.5-5 
µm will be deposited in respiratory airways, and greater than 5 µm will be impacted in the 
mouth/throat [37–42].  
2.1.2.2 Pulmonary Mucosa and Innate Immunity 
Additionally, the lung has several barriers once particles deposit. Pulmonary 
secretions of mucus and surfactants are necessary for homeostasis, vital in trapping and 
removing foreign particulate through mucociliary clearance (through beating of cilia), and 
important in immune regulation [43–46]. The mucosa is a viscoelastic material described 
as a “gel-on-brush” model where it is compartmentalized into two distinct regions: a more 
viscous layer composed of secreted mucins on top of the less viscous periciliary layer 
which contains membrane-tethered mucins [47]. Goblet cells and sub mucosal glands in 
the upper airways secrete mucins such as MUC5AC and MUC5B. The dysregulation of 
these mucins has been shown to be important in asthma, iPF, and CF [48–51]. Tethered 
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mucins such as MUC1, MUC4, and MUC16, are a direct host barrier to the epithelial 
surface, play a role in intracellular signal transduction and have been shown to modulate 
the immune response to pathogens [52,53]. Club cells secrete additional proteins into the 
mucosa such as glycosaminoglycans and uteroglobin, a potent immunomodulator [54–57]. 
In diseased states there is often impaired mucociliary transport, overexpression of mucin, 
higher viscosity mucus, increased exogenous proteases, and abnormal osmolarity 
[46,48,58,59]. This complex network of mucins and surfactants must be bypassed to target 
lung epithelial cells or interstitial fibroblasts, and nanoparticles smaller than 300 nm are 
needed for efficient endocytosis [5,12,60–64].  
Furthermore, phagocytic innate immune cells such as dendritic cells and 
macrophages line the airways and are important first responders in immune surveillance. 
Pulmonary macrophages can be subdivided into at least three distinct populations: 
bronchial, interstitial, and alveolar macrophages. Each population occupies different 
compartments of the lungs and they have different developmental pathways (fetal vs bone 
marrow) [65–67]. Interstitial macrophages function in tissue remodeling and maintenance, 
antigen presentation, influence dendritic cell function, and have differential 
immunomodulatory reactions than alveolar macrophages [65–70]. Tissue-resident alveolar 
macrophages are efficient at initiating and resolving pulmonary inflammation, 
communicating with alveolar epithelium, and regulating neutrophilic response [71–73]. 
One of the primary roles of alveolar macrophages is to phagocytose foreign particulate; 
while targeting of alveolar macrophages for therapeutic purposes is possible [17,74], 
delivery of therapeutics to other cells of interest (e.g. epithelial) is made more difficult by 
their phagocytic ability. This poses a difficult challenge for pulmonary delivery, as alveolar 
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macrophages can rapidly phagocytose particles with geometric diameters within the 
optimal 0.5-5 µm range aerodynamic [17,40,75,76].  
2.1.2.3 Strategies for Pulmonary Delivery 
These pulmonary barriers dictate that for efficient particle delivery, the particle 
requires an aerodynamic diameter between 0.5-5 µm and a geometric diameter greater than 
6 µm. Additionally, a nano-scale size is necessary for efficient cellular endocytosis and to 
pass the mucosal barrier. Current strategies for addressing these conflicting design criteria 
for aerodynamic and geometric size include the use of porous polymers and swellable 
microparticles. By lowering the density of the microparticles, large porous particles 
provide an aerodynamic diameter between 1-5 µm and a geometric diameter greater than 
6 µm, thus increasing residence time after deposition in the lungs [40,77,78]. While 
swellable microparticles in their relaxed, dry state provide the correct aerodynamic size for 
lung delivery, they swell in the humid lung environments to a size capable of avoiding 
rapid macrophage clearance [79–82]. However, once these microscale carriers reach the 
deep lung, intracellular delivery and transport across mucosal surfaces remain significant 
challenges.  
Nano-in-Micro particles have been previously reported for intestinal [83,84] and 
lung delivery [79–82], and the Roy Lab has previously reported a proof-of-concept trypsin-
responsive crosslinker with 60% w/v microgels for pulmonary delivery [79]. Poly(ethylene 
glycol) based hydrogels with protease responsive backbones have been widely used to 
respond and degrade to the cellular microenvironment [85–87]. Including an enzyme-
responsive peptide allows the microparticles to degrade rapidly in diseased airways with 
high enzymatic burden and thus release encapsulated therapeutic nanoparticles. These 
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nanoparticles are physically entrapped in the hydrogel network allowing the nanoparticle 
formulations to be easily exchanged for the desired therapeutic target. Microparticles in 
airways with low enzymatic burden typical of heterogenous diseases, should be cleared 
without releasing the nanoparticles – thus lowering side effects. Here, we study the impact 
of reducing starting polymer concentrations for the microgel formulation to avoid rapid 
clearance using two different crosslinkers, trypsin-responsive (CGRGGC) and neutrophil 
elastase-responsive (CGAAPVRGGGGC) adapted from the Anseth Lab by incorporating 
cysteine groups [88]. A neutrophil elastase responsive peptide was chosen as this protease 
is well known to be involved in various acute and chronic pulmonary inflammatory 
diseases [4,89–92]. We report an improved Michael Addition During (water-in-oil) 
Emulsion (MADE) method, which provides faster reaction kinetics during fabrication 
while avoiding degradative conditions caused by factors such as UV light, high 
temperatures, and organic solvents that could denature biologic drugs or sensitive 
therapeutics.  
 Polymers and Hydrogels 
Polymers are large molecules composed of repeating subunits and can be derived 
from natural or synthetic sources. Hydrogels are constructed from a network of crosslinked 
hydrophilic polymers allowing the three-dimensional network to hold large amounts of 
water in their swollen state—with the mass fraction of water in the hydrogel higher than 
the mass fraction of the polymer. Hydrogels can be fabricated with either natural or 
synthetic polymers. Many natural hydrogels are inherently bioactive, allowing cells to 
recognize and respond to the hydrogel (e.g. cellular adhesion) without additional 
modifications; however, they can be mechanically weak and have inconsistent batch-to-
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batch variability [93,94]. Synthetic polymers offer a high degree of control over properties 
such as manufacturing quality control, chemical functionality, and hydrogel mechanical 
properties; however, they are not inherently bioactive requiring modification for cellular 
interactions [93–96].  
Natural polymers include chitosan, collagen, and fibrinogen. Chitosan is a cationic 
polymer created by deacetylation of chitin, found in crustacean exoskeletons, and has been 
used in applications ranging from bone and cartilage repair to microparticle drug release 
[97–102]. Collagen and fibrin are both animal derived polymers; collagen is an abundant 
mammalian extracellular matrix components and fibrinogen is a blood circulating 
glycoprotein that is enzymatically cleaved by thrombin to spontaneously polymerize 
creating a fibrin network. Collagen and fibrin-based hydrogels have been used for multiple 
applications including vasculogenesis, chondrogenesis, therapeutic assays, and drug 
release [103–110]. 
Synthetic polymers such as polyvinyl alcohol (PVA), poly(lactic-co-glycolic acid) 
(PLGA), and polyethylene glycol (PEG). PVA, PLGA, and PEG have all been used for 
similar applications as natural polymers as well as in combination as natural/synthetic 
hydrogels [111–114]. PEG is a particularly useful platform as it can be modified with 
different functional groups allowing for a high degree of flexibility in the design and easy 
incorporation of biologics and biologically relevant peptides [105,115–118].   
 Current Models of Pulmonary Disease 
Although site-specific drug delivery with polymeric particles to the lung may be 
beneficial, pre-screening effective therapeutics for pulmonary fibrosis disorders such as 
iPF and CF is complicated by the lack of representative in vitro and in vivo models. These 
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diseases cause severe lung damage that eventually leads to respiratory failure and patient 
death. iPF is estimated to affect 3 million people with a life expectancy of 2.5-5 years after 
diagnosis [33,119]. CF is a genetic disorder with approximately 30,000 people diagnosed 
in the US and an estimated 10 million carriers of one of 1800 different mutations to the 
cystic fibrosis transmembrane conductance regulator (CFTR); CF has a median age of 
death of 30.7 years [120].  
Mouse models are often used for preclinical testing of pulmonary therapeutics. 
Small molecules such as lipopolysaccharide (LPS), N-acetylated proline-glycine-proline 
(PGP), and bleomycin are delivered directly to the mouse lungs to induce acute (LPS) or 
chronic (PGP) neutrophilic inflammation and fibrosis (bleomycin) [19,73,121,122]. While 
these models can replicate some aspects of inflammation, they do not recapitulate the 
underlying physiology. Although some genetic based models exist, such as CFTR 
knockout and mutant mice for CF, these models lack the severe human lung pathology 
since a compensatory mouse epithelial anion channels prevents CF knockout/mutant mice 
from replicating the lower airway extracellular barriers present in human CF diseases  
[20,21]. Ferret and piglet CF knockout models and dog, cat, donkey and horse pulmonary 
fibrosis resemble aspects of human disease, but these models are less accessible [19–21].  
Current three-dimensional in vitro models for the respiratory airways include 
decellularized tissue scaffolds, spheroid/organoid cultures, and air-liquid interface (ALI) 
cultures. Lung organoids refer to self-assembling structures generated from basal 
epithelium. These organoid cultures are useful as medium to high throughput models for 
screening the effects of modulators on epithelial cells; however, they lack lung-relevant 
extracellular barriers and do not recapitulate all of the complex structures such as the highly 
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vascularized respiratory airways [58,123–129]. ALI cultures are commonly used as they 
replicate relevant epithelial morphology (pseudostratified, ciliary movement, mucus 
production, polarity, and tight junctions) and are even commercially available (Epithelix). 
ALI cultures have been developed to replicate the neutrophil extravasation and activation 
in inflammation and CF using CF patient airway supernatant [130]. Microfluidic based 
ALI models have been able to recapitulate the pseudostratified epithelium and monolayer 
endothelium or smooth muscle cells separated by a thing film polyester track etched or 
polydimethylsiloxane membrane; however, to recapitulate neutrophilic extravasation 
larger 10 µm porous membranes are used [131–134] and the microvasculature and 
interstitial environment are not replicated.  
 Previous Work: Chitosan NP to Bypass Pulmonary Mucosa 
2.1.5.1 Introduction 
Chitosan is a mucoadhesive polysaccharide. Its cationic nature allows it to be easily 
coupled to negatively charged payloads including nucleic acids and certain proteins. 
Because of its mucoadhesive properties, chitosan nanoparticles have been formulated for 
delivery to mucosal surfaces such as ocular, intestinal, and pulmonary [100,102,135–138]. 
By entrapping into the mucus, the nanoparticles are able to increase their residence time 
and can act as a drug depot, increasing the time available for therapeutic release and 
nanoparticle efficacy [136,139]. However, for intracellular epithelial targets, mucus 
penetrating particles may be more appropriate to efficiently bypass the mucus and be 
endocytosed by the epithelium [9,12,64,114]. Chitosan modified with 2-3% imidazole 
acetic acid (IAA) has been shown to have increased buffering capacity, higher solubility at 
physiologic pH, and improved nucleic acid delivery in vitro and in vivo [140,141]. Here, 
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we adjusted the modification protocol to increase the IAA modification of chitosan that 
appears to adjust the mucoadhesivity of the chitosan nanoparticles and show increased 
epithelial uptake of fluorescent nanoparticles in in vitro air-liquid interface models. 
2.1.5.2 Materials and Methods 
Imidazole Modification of Chitosan: Imidazole modified chitosan (Chitosan-
IAA) was synthesized by utilizing sulfo-NHS/EDC chemistry to link 4-imidazole acetic 
acid (IAA, Sigma Aldrich) to the primary amines of 83% de-acetylated chitosan (Protasan 
UP-CL113, MW 83kDA, Novamatrix). Briefly, IAA was dissolved at 10 mg/mL in 0.1 M 
MES buffer and brought to a pH of 4.5-6. 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC, Sigma Aldrich) was added to the solution in a 5 M excess to the IAA 
along with sulfo-NHS (Sigma Aldrich) to a concentration of 5 mM. This is reacted for 15 
minutes before being quenched with 2-mercaptoethanol. The solution pH was then raised 
to 7. Chitosan dissolved in PBS at 10 mg/mL was then added to this solution and allowed 
to react while rotating for 2 hours. The Chitosan-IAA solutions were dialyzed against 5mM 
HCl for 2 hours twice and DI water twice for 6-12 h, then lyophilized for 48 hours. The 
imidazole to chitosan ratio was adjusted to produce chitosan-IAA polymers with different 
levels of modification at 20 and 40%. For the 83% deacetylated chitosan, 208 kDa chitosan 
(Chitoceuticals GMP Compliant Chitosan, Heppe Medical Chitosan, Halle Germany) 
formulation, the reaction of chitosan with the IAA solution was reduced to 1 hour.  
IAA Modification Characterization: In order to characterize the degree of 
modification of chitosan-IAA, the strong UV absorbance of IAA at 230 nm was measured. 
Briefly, a standard curve of IAA was created in acetate buffer and compared to known 
concentrations of chitosan, chitosan-IAA, and acetate buffer at 230 nm. The standard curve 
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was used to determine the IAA concentration in the known chitosan concentration to 
approximate percent modification.  
Nanoparticles Fabrication: Nanoparticles were prepared by complexing chitosan 
with tri-poly phosphate via electrostatic interactions. Chitosan or chitosan-IAA was 
dissolved in acetate buffer (pH 4.5) at a concentration of 2 mg/mL. TPP was also dissolved 
in acetate buffer and added at a ratio of 5:1 (TPP:Chitosan) to the chitosan solution. This 
was vortexed in a 15 mL conical on high for 30 seconds and left rotating at room 
temperature for 30 minutes. The resulting particles underwent buffer exchange into PBS 
via centrifugation in 10K MWCO Amicon Ultra 4 centrifugal filters (AMD Millipore). 
Particles were resuspended in a 1M KCL solution and size and zeta were measured using 
a Malvern Nano ZS (Malvern Instruments) and used immediately after preparation. For 
fluorescently tagged particles, the particles solution was exchanged into a 0.2 M sodium 
bicarbonate buffer, pH 8.3, and VivoTag 645 (NEV11174, Perkin Elmer) was added to the 
new solution according to manufacturer’s instructions. After one hour of coupling, the 
nanoparticles were separated from unreacted dye by either dialyzing repeatedly in HCl and 
DI water for 24 hours in 40K MWCO Float-A-Lyzers (Spectrum Laboratories) or by using 
7k MWCO Zeba Spin Desalting Columns (Thermo Scientific). Chitosan nanoparticles 
were air dried on carbon tape and imaged using a Hitachi SU8230. Chitosan nanoparticle 
concentrations used for the experiment were the theoretical max concentration of chitosan 
mass resuspended in 1 mL of media/buffer.  
NuLi-1 and CuFi-1 Cell Culture: A vial of NuLi-1 was gifted by the Emory 
University Experimental Models Core (EMC) and CuFi-1 was graciously gifted by Dr. J. 
Zabner (University of Iowa). For liquid culture, cell lines were expanded in BEBM 
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supplemented with BEGM Single Quots (Lonza) with the Single Quots’ 
gentamycin/amphotericin B stocks substituted with 0.01% v/v gentamycin (Sigma), 0.05% 
v/v amphotericin B (Amresco), and 0.5% penicillin-streptomycin (Gibco). Culture surfaces 
were coated for 48 h to 1 week in 60 µg/mL human placental collagen IV (Sigma) before 
cell seeding. For ALI cultures, transwells were collagen coated, cells were seeded at 60,000 
cells per 24-well transwell in DMEM-F12 (Gibco) supplemented with 5% v/v FBS 
(HyClone), 0.1% v/v gentamycin, 0.05% v/v amphotericin B, and 0.5% v/v penicillin-
streptomycin. Media was added to both the apical and basal chambers. On day 2, media 
was exchanged for DMEM-F12, 2% Ultroser G (Emory University Experimental Models 
Core), and on day 7 the cultures were airlifted by removing the apical media. Transwells 
were fed every two days and the apical surface was rinsed with PBS at least once per week 
while trans-epithelial electrical resistance (TEER) was measured with an EVOM 2 (World 
Precision Instruments). 
hSAEC Culture: Primary human small airway epithelial cells (hSAECs) 
guaranteed for differentiation were purchased from Lonza (CC-2547S, lot #0000501938). 
Cells were expanded in PneumaCult-Ex Plus (STEMCELL Technologies), seeded, and 
differentiated according to manufacturer’s instructions in PneumaCult-ALI Media 
(STEMCELL Technologies).   
Fluorescent Immunostaining: Transwells were fixed in 4% paraformaldehyde 
(ThermoFisher Sci), the membrane and cells were then carefully excised from the transwell 
and washed in 1x TBS for 5 minutes. The membrane was then blocked for 2 h at room 
temperature in 5% goat serum with 0.5% triton X, incubated at 4C overnight with the 
antibodies in 5% goat serum, washed 2x in blocking buffer then, if needed, incubated in 
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secondary at 37C for 1 hour and mounted between coverslips using Prolong Gold with 
DAPI (ThermoFisher Sci.) Antibodies used included: 1:100 dilution ZO-1-Alexa Fluor 488 
(ThermoFisher Sci, clone 1A12) and 1:100 Tubulin Beta 4 (LSBio, TUBB4-clone 6C2) 
with 1:250 Goat anti-Mouse Alexa Fluor 647. 
Microscopy: Fluorescent images were collected on a PerkinElmer UltraVIEW 
VoX spinning disk confocal with a Hamamatsu C9100-23b back-thinned EM-CCD or 
Hamamatsu FLASH 4 sCMOS version 2 and Nikon 60x NA-1.49 TIRF oil objective; 
SAECs were imaged with the Nikon 40X NA-1.3 oil objective and the resulting picture is 
an extended focus Z-stack. 
Track Velocity Measurements: Images were captured on a PerkinElmer 
UltraVIEW VoX spinning disc confocal with a Hamamatsu C9100-23b back-thinned EM-
CCD and Nikon 60x NA-1.49 TIRF oil objective at a rate of 15.07 timepoints per second 
for 1 minute. Data were analyzed using Volocity software (PerkinElmer); track lengths less 
than 5 were removed. 
Statistical Analysis: Data were analyzed using GraphPad with a Shapiro-Wilk test 
for normality (α = 0.05). A two-way Anova (α = 0.05) (mixed model with variable n) with 
Tukey post hoc analysis was used with Chitosan nanoparticle data that passed Shapiro-
Wilk. Else, Kruskal-Wallis (α = 0.05) with Dunn’s multiple comparison test (with adjusted 
P value) was used for data within each timepoint that failed the normality test. 
2.1.5.3 Results and Discussion 
Chitosan Characterization: Chitosan was modified with imidazole acetic acid 
(IAA) up to 20 and 40% modification by adjusting the amount of IAA added during the 
EDC/NHS chemistry. Higher modification than the previously reported 2-3% was 
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achieved by including an NHS reaction step. Nanoparticles were fabricated from 
unmodified chitosan, chitosan:IAA 20%, and chitosan:IAA 40% by electrostatic 
interactions with the small molecule tripolyphospate (TPP). Chitosan:TPP, 
ChitosanIAA20:TPP, or ChitosanIAA40:TPP nanoparticles were then imaged by SEM, 
Figure 3. Nanoparticles were found to have mean sizes between 71-85 nm and a positive 
Zeta potential from 10-15 mv, Table 1. The nanoparticle size suggests that these particle 
formulations should be able to bypass the mucosal layer.  
Figure 3: Chitosan Nanoparticle SEM Images Chitosan nanoparticle formulations 
imaged by SEM  
Table 1: Chitosan Nanoparticle Characterization 
  Mean ± SD (nm) PDI ± SD Zeta (mv) 
Chitosan:TPP 74.89 ± 4.63 0.19 ± 0.02 11.83 ± 1.37 
ChitosanIAA20:TPP 71.73 ± 1.39 0.20 ± 0.04 12.78 ± 2.37 
ChitosanIAA40:TPP 81.55 ± 7.07 0.22 ± 0.01 13.63 ± 0.63 
 
Chitosan Nanoparticle Uptake by Human Epithelial Cells: To determine 
whether these particles would be endocytosed by lung epithelial cells, standard submerged 
liquid cultures of NuLi-1, a cell line derived from human airway epithelial cells with a 
normal-non-CF genotype [142], were treated with VivoTag 645 fluorescently tagged 
chitosan nanoparticles at 1, 5, and 10 µg/mL and at 6, 12, and 24 hours the cells harvested 
and run on a flow cytometer to measure VivoTag positive cells. Gates were set using an 
FMO control. For all three concentrations the un-modified chitosan had rapid increase in 
 20 
the percentage of cells positive for the nanoparticle dye followed by a slower increase in 
the percentage of cells positive for the ChitosanIAA20:TPP or ChitosanIAA40:TPP IAA 
modified chitosan nanoparticles, Figure 4. At 10 µg/mL all three formulations had greater 
than 20% increase at 6 hours; this concentration was chosen for the rest of the particle 
delivery experiments.  
Figure 4: Chitosan Nanoparticle Uptake by NuLi-1 in Liquid Culture  Dose dependent 
uptake in standard liquid cultures of NuLi-1 cells at (A) 1 µg/mL (B) 5 µg/mL (C) 10 
µg/mL (n = 6) at 6, 12, and 24 hours. Bars indicate statistical significance ( = 0.05) 
Chitosan Nanoparticle Uptake in Air-Liquid Interface Cultures: The uptake of 
particles was then tested on primary human small airway epithelial cells (hSAECs) and the 
cystic fibrosis cell line CuFi-1. CuFi-1 is a human immortalized cell line developed from 
a F508/F508 genotype [142]. The hSAECs showed the opposite response of the NuLi-
1 cells, with all 3 nanoparticle formulations greater than 20% at 6 hours and higher 
percentages of fluorescent cells for the IAA modified chitosan nanoparticles. These cells 
do not appear to endocytose the chitosan:TPP particles well, with the mean at 24 hours of 
33% while the 20 and 40% IAA modified particles were at 90 and 95% respectively, Figure 
5A. The CuFi-1 cells appeared impartial to any nanoparticle formulation and at 6 hours 
had the highest percentage of cells positive for VivoTag 645, which was over 80% for all 
three formulations, Figure 5B. 
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Figure 5: Chitosan Nanoparticle Uptake by hSAECs and CuFi-1 in Liquid Culture 
(A) hSAEC uptake of Chitosan nanoparticles (n=5) and (B) CuFi-1 uptake of particle 
formulations (n = 6). Bars indicate statistical significance ( = 0.05). 
Culture of epithelial cells at an air-liquid interface is a simple model of the human 
respiratory system that can recapitulate tight junction formation, mucus secretions, and 
cuboidal or columnar epithelium depending on the starting cell source. These cultures were 
used to understand how the nanoparticles might transport across the mucosal barrier. 
hSAECs, NuLi-1 and CuFi-1 were grown at an air-liquid interface for 5-6 weeks, with 
TEER measured weekly, then treated with VivoTag 645 tagged Chitosan:TPP, 
ChitosanIAA20:TPP, or ChitosanIAA40:TPP nanoparticles. hSAECs cultures were a 
cuboidal layer that formed tight junctions (Z01) and cilia with an adjusted TEER mean 
over 400 *cm2 week 5, Figure 6A-B. NuLi-1 and CuFi-1 were not expected to form cilia 
[142] and were only stained for tight junctions (Z01) and nuclei (DAPI). NuLi-1 formed a 
monolayer with mean adjusted TEER just 100 *cm2, which was lower than expected 
[142] but not uncommon for this cell line [143], Figure 6C-D; however, the cultures still 
visually produced mucus-like secretions on top of the cells. CuFi-1 formed more of a 
pseudostratified epithelium, with overlapping cells visible by the overlapping nuclei and 
tight junction formation, mean adjusted TEER 1800 *cm2, Figure 6E-F. Like the NuLi-
1, CuFi-1 also produced secretions visible when inspecting the transwells.  
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Figure 6: Chitosan Nanoparticle Uptake in Air-Liquid-Interface Cultures (A) Tight 
junction (Z01) and Cilia (TUBB4) staining of hSAECs and (B) corresponding TEER 
measurements (n = 80). (C) Nuclear (DAPI) and tight junction (Z01) staining of 6-week 
NuLi-1 cells cultured at ALI; image contrast was linearly adjusted for clarity, scale bar = 
10 µm. (D) corresponding TEER measurements (n = 85). (E) Nuclear (DAPI) and tight 
junction (Z01) staining of 5-week CuFi-1 cells cultured at ALI, scale bar = 20 µm and (F) 
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corresponding TEER measurements (n = 80). ALI culture at 6, 12, 24 h for (G) hSAECs 
(H) NuLi-1, and (I) CuFi-1 (n = 5-6). 2-way-Anova (α = 0.05).  
VivoTag 645 tagged Chitosan:TPP, ChitosanIAA20:TPP, or ChitosanIAA40:TPP 
nanoparticles were delivered to the apical side of the transwell cultures on week 5 (hSAEC 
and CuFi-1) or 6 (NuLi-1) of culture. All 3 nanoparticle formulations were able to transport 
across the hSAEC mucus layer and be taken up by approximately 36% of the cells at 24 
hours, Figure 6G. However, for the NuLi-1 at ALI, at 24 hours the cells were only positive 
for the Chitosan40IAA:TPP nanoparticle formulation, 53%, while the unmodified 
Chitosan:TPP and Chitosan20IAA:TPP were 7% and 6%, respectively, Figure 6H. In the 
CuFi-1 cultures, both IAA modified nanoparticles had percentage uptake at 15% and 17% 
relative to 3% for unmodified chitosan, Figure 6I. The final percentages for the CuFi-1 
uptake were lower than for the hSAEC and NuLi-1 cultures. However, these transwells 
were the only cultures that appeared to be pseudostratified, which suggests that the 
nanoparticles were only endocytosed by the top layer of epithelial cells. These results 
suggest the IAA modified chitosan is able to transport more quickly through CF-like 
mucosa. 
To determine whether the nanoparticle transport was representative of transport in 
human CF airway supernatant (ASN) nanoparticles were mixed with pooled patient CF 
ASN to measure track velocity changes between nanoparticle formulations, representative 
tracks Figure 7A. Track velocities increased with the higher modified IAA chitosan 
nanoparticles, Figure 7B,suggesting the IAA modified chitosan may be successful in 
transporting in human CF airways.  
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Figure 7: Chitosan nanoparticle formulation track velocity in CF ASN (A) 
Representative images of nanoparticle tracks, colors reference specific tracks picked up by 
Volocity, scale bar = 5.2 µm (B) Violin plots of the measured track velocities in CF ASN 
bars indicate statistical significance, Kruskal-Wallis with Dunn’s multiple comparison (α 
= 0.05, n > 100) 
208 kDa Chitosan Nanoparticles: To determine whether any of the trends would 
replicate with a higher molecular weight chitosan, nanoparticles were fabricated with an 
83% deacytelated 208 kDa chitosan. Nanoparticle formulations made with the higher 
molecular weight chitosan formulations doubled in size, Table 2. Nanoparticle 
formulations were then delivered to submerged hSAEC cultures since the 83 kDa 
nanoparticles had distinct differences in epithelial cell endocytosis. Similar trends in 
nanoparticle positive cells were seen compared to the smaller nanoparticles (Figure 5A), 
except at 24 hours, the unmodified Chitosan:TPP nanoparticles and Chitosan20IAA:TPP 
had higher percentages of nanoparticle positive cells, 68% and 92%, than the 
ChitosanIAA40:TPP nanoparticles, 45%, Figure 8A. For the air-liquid-interface culture, 
NuLi-1 were chosen since this culture formed a monolayer and showed distinct mucosal 
transport with the 83 kDa nanoparticles. The higher molecular weight chitosan IAA 
modified nanoparticles do not appear to be as efficient as the lower molecular weight 
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particles in transporting across the mucus secretions of the NuLi-1 cultures with percentage 
uptake at 7%, 6%, and 4% for Chitosan:TPP, Chitosan20IAA:TPP, and 
Chitosan40IAA:TPP. This clearly shows the transport of these larger particles are 
inefficient, Figure 8B-C.  
Table 2: 208kDa Chitosan Nanoparticle Size  
Mean ± SD (nm) PDI ± SD 
Chitosan:TPP 152.9 ± 0.93 0.22 ± 0.01 
ChitosanIAA20:TPP 131.1 ± 0.81 0.26 ± 0.00 
ChitosanIAA40:TPP 142.9 ± 2.71 0.28 ± 0.01 
 
Figure 8: 208 kDa Chitosan Nanoparticle Formulation Delivery (A) hSAEC 
submerged culture uptake of Chitosan nanoparticles (n=5) and (B) NuLi-1 air-liquid 
interface culture uptake of particle formulations (n = 6) and (C) corresponding TEER 
measurements. Bars indicate statistical significance ( = 0.05) 
 
2.1.5.4 Discussion and Conclusions  
The modification of chitosan with imidazole acetic acid was improved from 
previously published work reporting 2-3% IAA modification to controlled 20 and 40% 
modifications. These IAA modified chitosan nanoparticles enhanced nanoparticle transport 
through pulmonary mucosa in air-liquid interface cultures. This benefit appears to be 
dependent on the molecular weight of the chitosan and the correlating smaller sized 
particles. However, Novamatrix no longer produces the low molecular weight chitosan, 
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Protasan, and other low-molecular weight chitosan, such as Sigma Aldrich’s (Cat. # 
448869), resulted in particles larger than 200 nm. Fabrication of low molecular weight 
chitosan is a potential alternative [144–147].  
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CHAPTER 3. AIM 1: NANO-IN-MICRO IN VITRO 
CHARACTERIZATION 
This aim had two broad goals for in vitro characterization of the Nano-in-Microgel 
multi-stage system: (1) to characterize the Nano-in-Micro system using reporter 
fluorescent nanoparticles and (2) to fabricate therapeutically loaded nanoparticles for 
targeting neutrophilic inflammation through delivery in the Nano-in-Micro system.  
Pulmonary drug delivery is a non-invasive method for targeted delivery of 
therapeutics for the treatment of respiratory diseases such as asthma, idiopathic pulmonary 
fibrosis, or cystic fibrosis. For particle deposition in the respiratory airways and alveoli, 
the aerodynamic diameter of particles should fall between 1-5 µm, however, nano sized 
carriers are required for efficient endocytosis of intracellularly targeting small molecules 
or biologics. Additionally, alveolar macrophages rapidly clear particles with a geometric 
diameter in this 1-5 µm range. A nanoparticle-inside-microgel formulation could provide 
efficient, intracellular, deep lung delivery of nanoparticles and therapeutics. The microgel 
carriers are designed for (a) enzyme-triggered release of nanoparticles, (b) needed 
aerodynamic properties and (c) avoiding rapid clearance by alveolar macrophages. 
Additionally, the nanoparticles themselves have the benefit of preventing degradation of 
the therapeutics from these high levels of disease-related proteolytic enzymes, reducing 
rapid clearance, and allowing for efficient endocytosis.  
We updated the previously reported Michael Addition during (water-in-oil) 
Emulsion (MADE) method [79] to a maleimide-thiol reaction. The maleimide-thiol 
provides faster reaction kinetics during fabrication while avoiding degradative conditions 
such as UV light, high temperatures, and organic solvents that could denature biologic 
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drugs or sensitive therapeutics during encapsulation. We fabricated both trypsin- and 
neutrophil elastase-responsive polymeric Nano-in-Micro, and for the first part of this aim 
studied the impact of starting polymer concentrations (20-50% w/v) for the microgel 
formulation on size, proteolytic degradation, and in vitro phagocytosis using two different 
crosslinkers: trypsin-responsive (CGRGGC) [79] and neutrophil elastase-responsive 
(CGAAPVRGGGGC) [88]. The trypsin-responsive peptide was used to expand the 
previously reported MADE method. A neutrophil elastase responsive peptide was chosen 
as this protease is well known to be involved in various acute and chronic pulmonary 
inflammatory diseases and would be relevant for the second half of this aim 
[4,62,89,90,148].  
For the second part of this aim, several therapeutics were chosen in collaboration 
with the Tirouvanziam lab at Emory University to load into nanoparticle formulations: 
Roscovitine, Tanshinone IIA (TIIA), and Nexinhib20 (Nex20). Roscovitine is a cyclin-
dependent kinase inhibitor that appears to function as a partial corrector for the most 
common CF mutation, F508del, and modulated the innate immune system [149,150]. 
Tanshinone IIA is isolated from Salvia miltiorrhiza and is believed to be an anti-
inflammatory that has been shown to regulate myofibroblasts as well as macrophages 
during a bleomycin induced lung injury [151,152]. Nex20 has been previously shown to 
be a potent PMN exocytosis inhibitor of the intracellular target Rab27a that not only 
regulates exocytosis but also inhibits the up-regulation of the adhesion molecules CD11b 
and CD66b [153]. However, the poor solubility of Roscovitine, TIIA, and Nex20 in water 
is a significant disadvantage to therapeutic translation of the soluble drug often requiring 
the therapeutic be dissolved in DMSO prior to treatment. Each of these therapeutics is 
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encapsulated using an oil-in-water single emulsion into a poly(lactic-co-glycolic acid)-
poly(vinyl) alcohol (PLGA/PVA) nanoparticle. We then encapsulated these water-soluble 
PLGA nanoparticles into our elastase-responsive microgels for pulmonary delivery 
modulating PMN-driven inflammation and confirmed in vitro microgel degradation and 
PMN nanoparticle uptake. 
3.1 Methods 
 MADE Nano-in-Microgel Fabrication 
Microgels were fabricated using Michael Addition During Water-in-Oil Emulsion 
(MADE). Equimolar amounts of a di-sulfhydryl peptide (CGRGGC, CGAAPVRGGGGC; 
CHI Scientific) and a 4-arm PEG Maleimide (Mal, 10kDa, Laysan Bio) were dissolved in 
PBS. Nanoparticles (0.1 µm Blue Fluospheres, ThermoFisher) and 0.01 mg of DyLight 
650-4xPEG-mal or DyLight 488-mal (ThermoFisher, dissolved at 10 mg/mL in DMSO) 
were added to the PEG macromer solution. The PEG-peptide mixture was added to mineral 
oil with 1% v/v surfactant (Span 80/Tween 80, HLB = 5) and homogenized on a PRO 
Scientific D Series homogenizer for three minutes at 4000 rpm in a 35-40C water bath. 
The emulsion was then left rotating for a minimum of two hours at 37C. Microgels were 
removed from the surfactant and residual unreacted material by multiple centrifuge washes 
in water. To make non-enzyme responsive microgels, a 1 kDa HS-PEG-SH (Creative 
PEGWorks) was used in place of the peptide, and the solution pH lowered to increase the 
crosslinking time. Microgels were filtered through a 40 µm cell filter before use to prevent 




 Microscopy and Analysis  
Fluorescent images were collected either on a Zeiss 710 Laser Scanning Confocal 
Microscope with a 63X NA-1.4 oil Plan Apochromat objective or on a PerkinElmer 
UltraVIEW VoX spinning disk confocal microscope with a Hamamatsu C9100-23b back-
thinned EM-CCD and Nikon 100x NA-1.45 oil objective. Sizing of swollen particles was 
performed with the MATLAB function “imfindcircles”. Other image processing, particle-
size in oil, calculations, stitching, and three-dimensional reconstruction were performed in 
Volocity (PerkinElmer Inc., USA).  
 Rheometry 
Hydrogel storage and loss moduli were measured by dynamic oscillatory strain, 
and frequency sweeps using an MCR 302 Rheometer (Anton Paar) with a 9 mm diameter 
2° cone and plate set at 25°C. Bulk hydrogels were made in 4.5 mm diameter silicone 
isolators, crosslinked, then removed from the isolators and allowed to swell in PBS 
overnight. One gel per formulation was used to determine the linear viscoelastic range of 
the hydrogel using a strain amplitude sweep with an angular frequency of 10 rad/s; strain 
from the linear portion was then used for the oscillatory frequency sweeps. Frequency 
sweeps were run with the constant strain from ω = 0.1-100 rad/s or until at least six points 
were linear. 
 In-vitro Degradation  
Microgels were studied in both the absence and presence of enzyme using time-
lapse imaging of a loaded cell trap provided by the Lu lab [154]. The use of a cell trap 
allows for the imaging of Nano-in-Micro degradation over time with a high n (n > 100) per 
run. Once traps were loaded DyLight 650 labeled microgels, enzyme solutions were flown 
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into the trap, and the trap was fluorescently imaged every minute for 30 minutes on a 
BioTek Lionheart. Images were stitched and analyzed in Gen 5.02 (BioTek). De-identified 
CF pooled patient sputum, airway supernatant (ASN), was collected by the Emory 
Biospecimens Repository under protocols approved by the Institutional Review Boards at 
Emory University and Georgia Institute of Technology.  
 Pore Size Calculation 
The pore size of the microgels was estimated as described by Canal and Peppas 
[155]; these equations, (1-3), were designed to correlate the mesh size of a crosslinked 
network of a single polymer type and, as our microgels do not adhere to this requirement, 
can only act as an estimate.  The bond length, l (1.46 Å), molecular weight of the repeating 
unit, Mr (44 g/mol), and characteristic ratio Cn (4), were used from PEG in Equation 1. 
The average molecular weight between cross-links, Mc, was calculated from the combined 
PEG and peptide molecular weights, 5551.63 g/mol for trypsin-responsive and 6004.15 for 
Elastase-responsive. For the equilibrium polymer volume fraction, v
2,s
, (Equation 2) the 
swelling ratio, Q,  was calculated from the mean size in the swollen and relaxed states 
measured by microscopy; this was confirmed with previously reported swelling ratio of the 
60% w/v acrylate Trypsin microgels [79]. The values from both equations 1 and 2 were 
then used to solve for mesh size, ξ, Equation 3. 
Equation 1  (?̅?𝟎
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 Macrophage Uptake Study  
RAW 264.7 cells (ATCC) were cultured in DMEM media supplemented with 10% 
Fetal Bovine Serum (FBS) 100 U/mL/100 µg/mL Penicillin-Streptomycin (HyClone) in a 
37C incubator with 5% CO2. RAW cells were detached by scraping and stained with 
CellTrace Yellow (ThermoFisher) following manufacturer instructions, then incubated 
with 20-50% w/v Nano-in-Micro at a 1:1 ratio in a 96 well V-bottom plate. At 0.5, 1, 2, 6, 
and 12 hours the plates were moved to 4C, and the cells stained with Zombie Green 
(BioLegend) and fixed with Cytofix (BD Biosciences). Fluorescence was evaluated using 
a BD LSR Fortessa with a high-throughput system.  
 PLGA Nanoparticle Fabrication 
Nanoparticles were fabricated using a single emulsion solvent evaporation method. 
0.8-1 mg of therapeutic and 0.2 mg of fluorophore (Rhodamine B, Sigma Aldrich, or DiR, 
ThermoFisher Sci.), and 100-130 mg of Poly (D,L-lactide-co-glycolide) (PLGA RG502H, 
Sigma Aldrich) were dissolved in 2 mL of ethyl acetate. The PLGA mixture was then added 
to 4 mL of 2.5% w/v poly(vinyl) alcohol (PVA; Sigma) and sonicated using a Sonics Vibra-
Cell VCX130 with CV18 at 65% for 10 min on ice. The emulsion was then added to 50 
mL of 0.3% w/v PVA solution and magnetically stirred for 5 hours. The nanoparticles were 
centrifuged at 8000 g for 10 minutes, pellet discarded, and nanoparticles in the supernatant 
were then washed in DI water by centrifuging at 100,000 g for 30 minutes. After the second 
DI rinse, the nanoparticles were resuspended in 5 mL 1% w/v trehalose solution, snap 
frozen in LN, lyophilized for 48 h, and stored at -20C. Nanoparticles were resuspended at 
1 µg/mL in water and run on a Malvern ZetaSizer or NanoSight depending on fluorophore 
encapsulated to determine the mean particle size. Therapeutics attempted were: (R)-
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Roscovitine (Cayman Chemicals), Tanshinone IIA (Cayman Chemicals), Nexinhib20 
(Cayman Chemicals). Drug encapsulation was measured by degrading the PLGA particles 
in DMSO or NaOH and measuring the drugs’ absorbance against a standard curve using a 
BioTek Synergy HT plate reader; Roscovitine: λ = 290, Nex20: λ = 290, TIIA: λ = 290. 
Endotoxin levels were tested using a chromogenic LAL kit (ThermoFisher) following 
manufacturer’s instructions.  
 PLGA Nano-in-Micro Fabrication 
The PLGA nanoparticles can be encapsulated into the microgel formulation as 
previously described with minor modifications to the preparation of the PEG precursor 
solution. The PLGA nanoparticles were resuspended at 10 mg in 80 µl of PBS, allowed to 
dissolve, and sonicated for 5 minutes. This was then used to dissolve the 4-arm PEG MAL 
precursor solution before following the rest of the MADE method. 
 PMN in vitro Transmigration  
This assay was performed as previously reported [130]. Briefly, PMNs were 
isolated from health donor’s blood, according to an approved Emory University 
Institutional Review Board protocol, using Polymorphprep (Alere Technologies AS, Oslo, 
Norway) as per manufacturer protocol. Purified neutrophils were then loaded on the 
transmigration chamber. Transmigration and following incubations were performed using 
100 nM of Leukotriene B4 (LTB4) (EMD Millipore) in RPMI or airway supernatant from 
CF sputum. The uptake of fluorescent microgels was then assessed 10 hours post 
transmigration by directly incubating PMNs recruited apically with microgels at a 1:10 
ratio (PMN to microgel) in either CF ASN or RPMI for 30 and 60 minutes and quantified 
using flow cytometry (n = 1). 
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 Statistical Analysis 
Data were analyzed using GraphPad Prism with a Shapiro-Wilk test for normality 
(α=0.05). A one-way Anova (α = 0.01) with post-hoc Tukey’s test with an adjusted P value 
for multiple comparisons or for two factors a two-way Anova (α = 0.01) with Sidak post 
hoc analysis was used with data that passed Shapiro-Wilk. Where applicable, a Mann-
Whitney (α = 0.01) or Kruskal-Wallis (α = 0.01) with Dunn’s test was used for data that 
failed Shapiro-Wilk. 
3.2 Results and Discussion 
 Nano-in-Microgels for Aerodynamic and Geometric Size 
Microgel formulations were made at 20, 30, 40, 50% w/v starting polymer 
concentration to assess the effect on microgel size, degradation, and macrophage 
phagocytosis. 4-arm PEG Maleimide was crosslinked with a trypsin-responsive 
(CGRGGC) or neutrophil elastase-responsive (CGAAPVRGGGGC) peptide backbone via 
crosslinking of the thiols on the cysteine residues. A maleimide-thiol reaction was chosen 
for the Michael Addition During water-in-oil Emulsion because of the faster kinetics 
relative to an acrylate-thiol [156]. By using both trypsin- and elastase-degradable 
crosslinker, we show the versatility of the multi-stage system, whereby the crosslinker can 
be exchanged for different disease-related protease responsive sequences. These peptides 
allow for the controlled degradation of the microgels by proteases to release their 
nanoparticle cargo, schematic representation in Figure 9A. 
To fluorescently label the microgel for imaging and flow cytometry, a DyLight 
650-4x-PEG-Maleimide or DyLight 488 Maleimide was added to the 4x-PEG-Maleimide 
precursor solution; representative images of a DyLight-650 labeled microgels with 
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encapsulated 60 nm carboxylated polystyrene beads can be seen in Figure 9B. DyLight 650 
labeled the microgels clearly for all 20-50% w/v for flow cytometry, but not 60% w/v 
formulation, Figure 10A, DyLight 488 labeled in Figure 10B. Carboxylated beads (60 nm) 
can be seen in more than 89% of the microgels by flow cytometry, Figure 10B (orange). 
Encapsulation efficiency of the 100 nm Blue Fluospheres (used for in vivo) for each 
formulation was between 30-40% with total nanoparticles encapsulated (~1e11) in the 
microgels within the same order of magnitude as theoretical maximum (3.6e11), Table 3. 
 
Figure 9: Nano-in-Micro Representative Schematic and Images (A) Schematic of 
Nano-in-Micro particle formulation and protease dependent microgel degradation and 
nanoparticle release (B) Representative image of a 20% trypsin-responsive DyLight 650 
labeled microgel encapsulating 60 nm Dragon Green polystyrene beads; scale bars 5 µm, 





Figure 10: Flow Cytometry Characterization of Nano-in-Micro  (A) Accuri signal of 
fluorescently DyLight 650 (DL) labeled microgels for the following formulations; no 
DyLight 650 (cyan), Trypsin-responsive 20% (blue), 30% (light green), 40% (dark green), 
50% (purple), 60% (light purple) (B) Microgels without Dragon Green (DG) nanoparticles 
(light green), with 60 nm Dragon Green nanoparticles (orange), and microgels labeled with 
DyLight 488 (red). (C) Microgel fluorescence on Day 0 for 20% w/v Trypsin (Light Green) 




Table 3: 100 nm Blue Fluosphere Encapsulation in Microgels 
% w/v % Encapsulation # NP Encapsulated  
Trypsin (CGRGGC) 
20 34% 1.2E+11 
30 30% 1.1E+11 
40 42% 1.5E+11 
50 31% 1.1E+11  
Elastase (CGAAPVRGGGGC) 
20 31% 1.2E+11 
30 33% 1.2E+11 
40 33% 1.1E+11 
50 32% 1.1E+11 
 
The geometric diameter of the microgels was measured with means between 4.5-
8.5 µm for each starting polymer concentration, Figure 11B, D.  Mean size generally 
increased with the increase of starting polymer concentrations; however, none of the 
formulations were significantly different. The lowest size is limited by the imaging 
technique used for the measurement. 60% w/v microgels were not included in the studies 
as their yield was low and the viscosity of the solution was difficult to transfer to the 
homogenizer efficiently. Aerodynamic diameter (Da) is dependent on the geometric 
diameter (Dg), shape factor (1 for spheres) and density of the particle through the following 
relationship: Da = Dg*ρ0.5. Using the density of PEG as 1.13 g/mL, aerodynamic diameters 
of various microgel formulations were calculated and are shown in Table 4. Aerodynamic 
diameters of 1 to 5 µm are most suitable for deep lung deposition; this corresponds to a 
theoretical geometric size range of 0.94 and 4.7 µm for PEG based particles. This range is 
represented by dashed grey lines on Figure 11A, C. The actual aerodynamic diameter 
measured by a next generation impactor, after developing a dry powder formulation, would 
be necessary to account for microgel aggregation, density, and shape factor. 
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Figure 11: Trypsin- and Elastase-Responsive Microgel Size Distribution (A) trypsin- 
and (C) neutrophil elastase-responsive in the relaxed state and in the (B, D) swollen state. 
The dashed grey lines on the relaxed state are the min-max theoretical aerodynamic 
diameter range. Each violin plot is from max to min with median (black line) and quartiles 
labeled, n > 200 for each measurement. 
Table 4: Calculated Aerodynamic Diameters  
Trypsin (CGRGGC) 
% w/v Mean (µm) Std Dev. 75 Percentile 
20 1.6 1.0 1.9 
30 2.1 1.4 2.8 
40 2.3 1.8 2.7 
50 2.6 1.7 3.4  
Elastase (CGAAPVRGGGGC) 
20 2.3 1.5 3.2 
30 1.8 1.1 2.4 
40 1.8 1.1 2.2 
50 2.1 1.8 2.8 
 
  Greater Than 95% of Microgels Degrade Within 30 Minutes in vitro  
In order to confirm enzymatic degradation of the microgels, Nano-in-Micro 
particles were loaded into single cell traps [154] then exposed to the relevant proteases and 
imaged over time (Figure 12A).  Trypsin-responsive microgels were degraded in 0.01 
mg/mL of trypsin (≥ 90 u/mL); for all formulations, 95% of microgels degraded within 20 
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minutes.  These studies were repeated with the neutrophil elastase microgels degraded in 
de-identified pooled cystic fibrosis patient sputum. For all elastase formulations, 95% of 
microgels degraded within 25 minutes of exposure to the sputum. It is also possible that 
the protease-responsive crosslinkers be non-specifically degraded by other proteases 
present; e.g., cathepsin S on the elastase peptide (probability of cleavage found using 
PACMANs [157]). Non-enzyme degradable 20% w/v microgels were fabricated by 
crosslinking with a dithiol PEG and exposed to 0.01 mg/mL of trypsin (≥ 900 u/mL) as a 
control to show the peptide crosslinker is necessary for enzyme-responsive degradation. 
The fluorescence trend of the non-enzymatically degradable PEG microgels followed that 
of several sets of trypsin and elastase crosslinked microgels tested for photobleaching of 
the microgels; the mean at 25 minutes is 91%, Figure 12B. Interestingly, we did not observe 
a difference in degradation when varying polymer concentrations. This could be due to 
either the limits of the measurement method (1-minute intervals) or simply the 
polydispersity of the microgels and overlap in size of the different groups. It is also possible 
that the protease concentration is high and the kinetics of degradation is much faster than 
the increase in the number of crosslinks. The release of 100 nm nanoparticles will follow 
the degradation curve as the theoretical pore size calculated [155] is smaller than the 
nanoparticles, Table 5. 
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Figure 12: Trypsin- and Elastase-Responsive Microgel Proteolytic Degradation (A) 
Representative images of microgels crosslinked with PEG, trypsin-, or elastase-responsive 
peptides degrading in the presence of their respective enzymes (0.01 mg/mL trypsin; CF 
patient sputum for elastase). (B) Mean ± SEM plots of the percent of microgels remaining 
in the trap over 30 minutes for PEG microgels exposed to trypsin or photobleached 
trypsin/elastase microgels (N = 5), and enzyme degradation of trypsin (N = 5), and elastase 
(N = 3). Trypsin- and elastase- responsive microgels were tested for each 20-50% w/v 
starting polymer concentration with 95% of trypsin responsive microgels degrading in 20 
minutes and 95% of elastase responsive degrading in 25 minutes. 
Table 5: Theoretical Pore Size 












 20-50% w/v Bulk Hydrogels are Relatively Soft 
Since macrophage phagocytosis has been shown to be interdependent on size and 
mechanical properties of the particles [158,159], we next measured storage (G’) and loss 
(G”) moduli of the bulk hydrogels. For the trypsin-responsive crosslinker, the 20% w/v had 
significantly lower loss modulus than the 40 and 50%. Furthermore, both trypsin and 
elastase crosslinker 20% w/v formulation had lower storage modulus than the 40 and 50% 
w/v bulk gels. However, across all formulations, the hydrogels are relatively soft (10kPa), 
Figure 13; the measurements for 20-50% w/v with trypsin or elastase peptide crosslinkers 
are grouped along the x-axis by G' and G''. 
Figure 13: Storage and Loss Moduli for Trypsin- and Elastase- Responsive gels Bulk 
hydrogels with starting polymer concentrations from 20-50% w/v (n = 8). Bars within 
formulation are group mean ± SD. Horizontal bars represent statistical significance, 
Kruskal-Wallis with Dunn’s multiple comparison test (α < 0.01) 
 Increased Polymer Concentration Slows RAW 264.7 Phagocytosis 
To study macrophage phagocytosis in vitro, DyLight 650 labeled Nano-in-Micro 
particle formulation (20-50% w/v) were mixed and incubated with RAW 264.7 cells at a 
1:1 cell:particle ratio. At 0.5, 1, 2, 6, and 12 hours of incubation, the cells were fixed and 
analyzed using flow cytometry. After fixing, a small sample of cells from each treatment 
group was placed on a slide and imaged on a spinning disc confocal. A representative 
image (Figure 14A) showed that multiple particles could be phagocytosed by the same 
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cell.  Over time, the percentage of macrophages that were positive for the microparticles 
increased for each formulation of microgel; however, the higher polymer concentrations 
had a lower percentage of macrophages positive for the microgels across time, potentially 
due to a combination of the slight differences in sizes and/or the rheological properties of 
the microgels. This trend was observed for both the trypsin- and elastase-responsive 
microgels, Figure 14B.  
Figure 14: RAW 264.7 Macrophage Microgel Uptake (A) Representative images of a 
CellTrace Yellow labeled macrophage with 100 nm Blue Fluospheres, and DyLight 650 
labeled microgels, linearly contrasted for clarity. (B) Microgel uptake measured by flow 
cytometry of the percentage of DyLight 650 positive RAW 264.7 macrophages for trypsin- 
(n=6) and elastase- responsive (n=12) microgels over time. Kruskal-Wallis with Dunn’s 
multiple comparison test, bars represent statistical significance, α < 0.01. 
 Therapeutic Loading into PLGA Nanoparticles  
An oil-water single-emulsion solvent evaporation technique was used to 
encapsulate Roscovitine, Nex20, and TIIA with a red or near-IR dye. A single-emulsion 
was chosen as each of the drugs have poor water solubility and thus only needed the oil 
phase for encapsulation while producing sub-300 nm particles; mean size using this method 
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was below 200 nm.  Roscovitine Rhodamine B PLGA nanoparticles mean size was 162.9 
+/- 1.8 nm with a polydispersity index (PDI) of 0.23 measured by ZetaSizer. Nex20 DiR 
PLGA nanoparticle size was measured using a NanoSight since the DiR dye is not 
compatible with the laser used by the ZetaSizer. Nex20 DiR PLGA nanoparticles mean 
size was 145.6 +/- 3.3 nm with a D90 of 196.5 +/- 8.9 nm; Tanshinone IIA DiR PLGA 
nanoparticles were 140.7 +/- 1.3 nm with a D90 of 181.1 +/- 4.8 nm; DiR only PLGA 
nanoparticles mean size was 177.2 +/- 4.3 nm with a D90 265 +/- 9.5 nm. Nanoparticles 
(> 60 mg/mL) were degraded to measure the therapeutic loading efficiency. Roscovitine 
Rhodamine B PLGA nanoparticles were loaded at 3.09 µg/mg Roscovitine to PGLA 
formulation for a 49.1% encapsulation efficiency. Nex20 was loaded at 1.48 µg/mg of 
PLGA formulation, 21% encapsulation efficiency. TIIA was loaded at 0.05 µg/mg of 
PLGA formulation for a 6.6% encapsulation efficiency. Although Roscovitine, Nex20, and 
TIIA all loaded in the PLGA nanoparticles, the TIIA loading efficiency was low and may 
need a modified particle formulation for higher therapeutic delivery. Endotoxin levels were 
tested on 1 mg/mL of nanoparticles using a chromogenic LAL assay kit; DiR only was 
0.31 EU/mL, TIIA DiR was 0.23 EU/mL, and Nex20 DiR nanoparticles were 0.24 EU/mL. 
 PLGA Loading into Nano-in-Micro 
The PLGA Nano-in-Micro was designed for neutrophil elastases mediated 
degradation. Inflammation in diseases such as asthma, chronic obstructive pulmonary 
disorder (COPD), and cystic fibrosis is often mediated by polymorphonuclear neutrophils 
(PMNs). One of the hallmarks of PMN driven inflammation  is the highly proteolytic 
microenvironment created by the release of proteases such as neutrophil elastase (NE) and 
metalloproteinases (MMP) [62,90,91,160,161]. Once the Nano-in-Micro is delivered, the 
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microgels degrade releasing the nanoparticles; the therapeutic nanoparticles can then 
modulate PMN exocytosis activity (e.g. Nex20), reducing the exogenous elastase, creating 
a negative feedback loop for future doses. Since the PLGA formulations included a near-
IR dye, the DyLight 640-4xPEG Mal was exchanged for a DyLight-488 Mal to label the 
microgel (4x-PEG Mal DyLight 488 were unavailable). Representative images in Figure 
15A showed many microgels appeared to have large aggregates of the PLGA formulation, 
suggesting poor loading may be due to insufficient dispersion of the nanoparticles. The 
mean size of these particles was 3.2 µm with a range of 8 µm. Flow cytometry showed the 
microgels incorporated the DyLight 488 dye (100% positive), Figure 15B; however, the 
PLGA formulations (DiR) were found to have poor distribution within the microgels, 
ranging from 14-18% of the microgels positive for the DiR nanoparticles, Figure 15C. This 
distribution was improved from 18% to 48% by including a sonication step during 
fabrication when the PLGA nanoparticles were resuspended in PBS before encapsulation 
within the microgels, Figure 15D.  
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Figure 15: PLGA Nano-in-Micro (A) Representative images of DyLight 488 labeled 
elastase-responsive microgels loaded with DiR labeled PLGA nanoparticles, images 
linearly contrasted for clarity, scale bar = 20 µm. (B) BD Accuri flow profiles of microgels 
loaded with DiR PLGA nanoparticles without DyLight 488 loading (light pink), DiR with 
DyLight 488 (red), Nex20 DiR PLGA with DyLight 488 (blue), and TIIA DiR PLGA with 
DyLight 488 (orange). (C) Microgels without nanoparticles (green), 17 % loaded with DiR 
PLGA (red), 18 % loaded with Nex20 DiR PLGA (blue), 14 % loaded with TIIA DiR 
PLGA (orange) (D) Increase in Nex20 PLGA nanoparticles encapsulation from 18 to 48 
% after sonication during fabrication (light blue). 
Prior degradation results were confirmed by repeating the single-cell trap Nano-in-
Micro degradation with Nex20 DiR PLGA loaded elastase-responsive 20% w/v Nano-in-
Microgels, Figure 16A. The degradation followed similar trends as Figure 12, with 90  
2.5% of the microgels degraded within 25 minutes and 95% degraded in 30 minutes; the 
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slight increase in degradation time is most likely due to using a different pooled CF airway 
supernatant (ASN) sample. The Nano-in-Microgels were then tested by the Tirouvanziam 
lab in an in vitro transmigration model, which uses the relevant biological milieu, i.e. CF 
ASN, for PMN transmigration (TRM) and allows the recapitulation of the in vivo PMN 
airway phenotype found in CF patients [130]. We measured nanoparticle uptake by these 
airway PMNs using 60 nm fluorescent (Dragon Green) carboxylated polystyrene 
nanoparticles encapsulated within un-labeled elastase-responsive microgels. LTB4, a 
leukotriene produced by leukocytes during inflammation, and CF ASN were used to 
transmigrate PMN in the in vitro system. These PMNs were then collected and exposed to 
the elastase-responsive Nano-in-Micro at a 1:10 ratio in either RPMI medium or additional 
CF ASN. This showed that the degradation of the microgels in the presence of CF ASN 
increased the percentage of PMN positive for the nanoparticle by 5-10% at 60 minutes, 
regardless of the transmigration milieu (LTB4 or CF ASN), Figure 16B. Additionally, 
when both PMNs transmigration and the Nano-in-Micro are in the CF ASN milieu, there 
is an increase in PMNs positive for the fluorescent nanoparticles.  Together, these data 
indicate that for efficient uptake of nanoparticles by airway PMNs, the elastase-responsive 
microgel must degrade first. Furthermore, there is an additive effect between the acquired 
PMN phenotype, imprinted by the transmigration condition (CF ASN vs LTB4), and the 
incubation milieu with the Nano-in-Micro system. This suggests that targeting of airway 
PMNs by the Nano-in-Micro system would be more efficient in pathological settings (CF 
ASN) rather than during the normal course of inflammation (LTB4). 
 47 
Figure 16: Elastase-Responsive Degradation and PMN Uptake (A) Nex20 DiR PLGA 
nanoparticles were encapsulated in 20% w/v elastase-responsive microgels, loaded into a 
single-cell trap, and imaged for 30 minutes with or without pooled CF airway supernatant 
(ASN); scale bar = 10 µm, mean  SEM, N = 3 (no CF-ASN), N = 6 (CF-ASN). (B) PMNs 
were transmigrated (TRM) by either LTB4 or CF ASN, then given Nano-in-Microgels in 
either RPMI media or CF ASN. PMN that transmigrate (TRM) in the CF ASN milieu 
readily show fluorescence of the nanoparticles encapsulated in NE-responsive microgels 
when the Nano-in-Micro is delivered to a CF ASN milieu rather than media alone (n = 1).  
3.3 Conclusions 
The purpose of these studies was to understand (1) how the starting polymer 
concentration of our Nano-in-Micro multistage particles influenced the size and in vitro 
degradation and phagocytosis and (2) the incorporation of immune mediating therapeutics 
into the Nano-in-Micro system. This in vitro work has further improved upon the MADE 
method by changing the chemistry for faster reaction kinetics, shown the incorporation of 
a disease-relevant protease-responsive peptide, and shown the flexibility in exchanging 
nanoparticles. These results provide a further understanding of how enzymatically-
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degradable multi-stage polymeric carriers can be used for pulmonary drug delivery. The 
following chapter will investigate the in vivo response to these multi-stage particles.  
  
 49 
CHAPTER 4. AIM 2: NANO-IN-MICRO IN VIVO 
CHARACTERIZATION 
The purpose of this aim is to understand how the Nano-in-Micro multi-stage system 
interacts with the innate immune cell environment in in vivo mouse models. The goals of 
this aim are: (1) characterize the phagocytosis and clearance of the Nano-in-Micro system 
in naïve mice following pulmonary delivery and (2) test the efficacy of the delivery system 
in an acute neutrophilic inflammation model using fluorescent reporter particles and 
immunomodulatory therapeutics.  
Polymorphonuclear neutrophils (PMNs) play a central role in the pathophysiology 
of several disorders, such as rheumatoid arthritis [162], systemic lupus erythematosus 
[163], acute lung injury [164], asthma [165], chronic obstructive pulmonary disease 
(COPD) [92], and cystic fibrosis (CF) [166]. Importantly, although PMNs have been 
considered short-lived and with little opportunity for plasticity, recent studies have 
challenged this dogma, particularly in chronic inflammatory diseases [150,167–169], 
suggesting prolonged PMN lifespan, active release of proteolytic mediators and thus 
opening new therapeutic opportunities. However, despite the role of PMNs and PMN-
derived mediators in shaping the clinical outcomes in disease, there is a clear lack of 
therapies and delivery methods allowing PMN-specific targeting in highly proteolytic 
microenvironments. 
One of the hallmarks of PMN-driven inflammation lung diseases, such as acute 
respiratory distress syndrome, CF, and COPD, is the highly proteolytic microenvironment 
created by the release of neutrophil elastase (NE) and metalloproteinases (MMP), such as 
MMP-9 [170]. Additionally, accumulation of these PMN-derived proteases leads to the 
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saturation of the antiprotease shield and unopposed proteolytic action, causing structural 
lung damage and decline in lung function [90,160]. The highly proteolytic 
microenvironment, as well as presence of other detrimental enzymes, such as 
myeloperoxidase, in the diseased areas of the lungs represent a current challenge for the 
effective delivery and preservation of the efficacy of the drugs aimed at targeting airway 
disease and inflammation [90,171–173].  
However, delivery of drugs encapsulated in nanoparticles represents a viable 
strategy to overcome the challenges of drug modifications induced by the 
microenvironment before they reach the cell of interest. Pulmonary drug delivery offers an 
alternative administration route that allows for site-specific delivery of therapeutics for 
respiratory airway disease; efficient localized delivery can potentially reduce the overall 
dose needed as well as reduce systemic toxicity from the therapeutic. The design of the 
Nano-in-Micro system not only allows the microgel to provide the needed aerodynamic 
size for deposition and geometric size to avoid rapid clearance (< 1 hour) but also takes 
advantage of the high proteolytic microenvironment for controlled release of the drug-
loaded nanoparticles. 
While particle deposition in the lungs is an important factor to the delivery of the 
Nano-in-Micro system, the aerodynamics of mice airways do not recapitulate those of the 
human airways. However, a naïve mouse model can be used to understand the in vivo 
response time frame for clearance by the mucociliary elevator and phagocytic innate 
immune cells. Additionally, an acute neutrophilic inflammation can be induced by 
administering lipopolysaccharide (LPS), a TLR-4 agonist, directly to the lungs; this model 
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predominantly recruits polymorphonuclear neutrophils (PMN). PMN peak in the tissue 
lysate at 2-4h, and around 12h in the bronchoalveolar lavage [174,175]. 
4.1 Methods 
 Ethical Statement  
All studies were performed according to protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) at the Georgia Institute of Technology, Emory 
University, and the University of Alabama Birmingham, and all methods were performed 
in accordance with the relevant guidelines and regulations. 
 Pulmonary Administration 
C57BL/6 and 8-12 weeks old female Balb/c mice (Jackson Laboratories) were 
maintained in pathogen-free facilities, given sterile water, and food (low alfalfa if used for 
imaging) ad libitum. Using a 1A-1C MicroSprayer Aerosolizer and FMJ-250 high pressure 
syringe assembly (Penn-Century, Inc.) for aerosolized delivery, mice were anesthetized 
with a Ketamine/Xylazine 80-100 mg/kg/10-20 mg/kg cocktail, positioned on an 
intubation table, endotracheally intubated with a 1.22 mm ET Tube (Hallowell EMC), and 
swollen Nano-in-Micro formulations (1e6 microgels in 50 µL) were injected. If there was 
device failure the mouse was marked for follow up and removed from data sets; all samples 
removed were marked within the relevant IVIS figures. For oropharyngeal aspirations, 
mice were anesthetized with isoflurane, placed on an intubation table, then the tongue was 
pulled and held with atraumatic forceps as the formulation was administered into the 
mouth, and the nose gently covered until the liquid was inhaled. Within experiments, the 
concentration of microgels was equal between formulations. After sacrificing the mice with 
sodium pentobarbital, perfusing the lungs with PBS through the right ventricle then 
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excising the lungs, the fluorescence intensity of the excised lungs was measured by 
imaging via IVIS Spectrum µCT (Perkin Elmer Inc.).  
 LPS Induced Acute Neutrophilic Inflammation 
5-week-old female C57BL/6 littermates (Jackson Labs) were maintained in a 
pathogen-free facility, given sterile water and food ad libitum. Mice were treated with 
either saline or 100 µg of LPS then for the fluorescent uptake study Nano-in-Micro 
formulation was delivered 2 h later and for the Nex20/TIIA study 1 h after injection. The 
time for Nano-in-Micro injection was shortened since at 2 h post LPS mice had significant 
difficulty in aspirating the particle formulation. Mice used for IVIS were given a low alfalfa 
feed diet to reduce fluorescence background.   
 Flow Cytometry 
Single cell suspensions were prepared using a gentleMACS tissue dissociator 
(Miltenyi) with 1 mg/mL of Collagenase D (Roche) and 0.1 mg/mL DNase I (Roche) in 
Opti-MEM (ThermoFisher), then strained through a 40 µm cell strainer. Red blood cells 
(RBC) were lysed using 1x RBC Lysis Buffer (eBioscience). The single cell suspension 
was then washed and stained with Zombie Aqua (BioLegend), incubated with Fc Block 
(BioLegend) then with fluorochrome-conjugated antibodies (BioLegend unless noted; 
clone used), and fixed with Cytofix (BD Bioscience). Antibodies used for the experiment 
in Figure 23 were: Ly-6G-BV711 (1A8), CD45-BV605 (30-F11), SiglecF-PE (BD 
Bioscience; E50-2440), CD11c-APC/Fire750 (N418), F4/80-PE/Dazzle™ 594 (BM8), 
CD11b-PE/Cy7 (M1/70). Cells were collected on an untreated littermate to set the gates 
with noise below 1% by FMOs (fluorescence minus one). The gating scheme for this 
experiment is illustrated in Figure 17; data were acquired on a BD LSR Fortessa flow 
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cytometer. For Figure 24-Figure 27, cells were stained with FC block and Zombie live/dead 
dye for 10 minutes on ice, followed by staining for 15 minutes on ice with antibodies 
against the following markers: CD45, Ly6G, Ly6C, MHCII, CD11b, F4/80, CD206, 
CD11c, SiglecF, and CD63. Cells were washed with PBS-EDTA (250 nM), fixed with 
Lyse/Fix PhosFlow reagent (BD Biosciences) and acquired on a FACS LSRII (BD 
Biosciences) and on a Cytoflex S (Bechman Coulter). PMNs were gated as CD45+, Ly6G+ 
and CD11b+ cells while macrophages were identified as CD45+, F4/80+, MHCII+, Ly6G- 
cells. Compensation and data analyses for all flow experiments were performed using 
FlowJo (TreeStar). 
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Figure 17: in vivo LSR Fortessa Gating Schematic Gating and FMOs for the flow panel. 
After gating for singlets cells were gated on CD45+ and although Zombie Violet live/dead 
fixable dye was included in the panel, due to the few number of cells in the final eosinophil 
and alveolar macrophage gates, the dead cells were included in the analysis. The CD45+ 
population was then bisected on Ly6G, with Ly6G+ labeled as neutrophils. The Ly6G- 
group was then bisected for SiglecF, the SiglecF+ population was then gated on CD11c 
and CD11b for eosinophils (CD11b+CD11c-) and alveolar macrophages (CD11b-
CD11c+). The SiglecF- population was then gated for the macrophage marker F4/80. 
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Figure 18: PMN and Macrophage Flow Cytometry Gating Scheme After singlet gating, 
PMNs were gated as CD45+Ly6G_CD11b+ while macrophages were gated as 
CD45+F4/80+MHCII+Ly6G- 
 Extracellular vesicles (EV) analysis 
EVs were isolated from the BAL using bead-based pulldown with Annexin V as 
per manufacturer’s protocol (SBI). Isolated EVs were stained with the EV marker ExoFITC 
(SBI) and anti-mouse neutrophil elastase (R&D systems). EVs were analyzed by flow 
cytometry on a Cytoflex S (Beckman Coulter). 
 ELISA 
NE and MMP9 concentrations were measured in the BAL of mice as per 
manufacturer’s protocol (R&D Systems). Cytokines from the plasma and BAL were 
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measured using a multiplex platform following manufacturer’s protocol (Meso Scale 
Diagnostic, V-PLEX mouse cytokines – 19 analytes). 
 Statistical Analysis 
Data were analyzed using GraphPad Prism with a Shapiro-Wilk test for normality 
(α=0.05). A one-way Anova (α = 0.05) with post-hoc Tukey’s test with an adjusted P value 
for multiple comparisons, or a two-way Anova (α = 0.05) with Sidak post hoc analysis was 
used with parametric data. Where applicable, Kruskal-Wallis (α = 0.05) with Dunn’s test 
was used for nonparametric data. 
Results 
 Microgels Begin Clearing Within 24h in Naïve Mice in vivo 
Based on our in vitro data, the degradation rate of the elastase-responsive microgels 
in CF airway fluid would occur within a short time frame (i.e., 30 minutes). Since the 20% 
w/v microgels had both the fastest and the highest percentage of RAW 264.7 macrophages 
positive for the microparticles in vitro, Figure 12, they were used to investigate how 
quickly the microgels would be cleared from the lungs in vivo, and to further understand 
how fast the protease-specific peptide crosslinked microgels must degrade to release their 
nanoparticles before being cleared. The trypsin-responsive crosslinker was selected 
because trypsin is a protease primarily found in the digestive system and should not be 
present in the lung, allowing us to primarily study clearance rather than degradation. Balb/c 
mice were treated with saline or 20% w/v trypsin-responsive Nano-in-Micro particles by a 
Penn-Century MicroSprayer aerosolizer, which demonstrated that microgels were present 
in all 5 lobes of the lungs as well as some interaction with SiglecF+ phagocytes (eosinophils 
or alveolar macrophages) confirmed by confocal microscopy, Figure 19.  
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Figure 19: Microgel Deposition in naïve Mouse Lungs Microgels were instilled in mice 
lungs, lungs were harvested immediately and frozen for cryosectioning. (A) 10x image of 
a DAPI microgel section of the lobes (scale bar 80 µm) B) SiglecF stained cells within a 
lung section (scale bar 16 µm) and (C) representative full lung section. (D) Ratio of 
microgels present to nuclei within each lobe, measured by Volocity, each point is an 
individual mouse and shows deposition of microgels in each of the lobes. 
To determine how quickly the microgel formulations would begin to clear during 
normal non-degradative conditions, 20% w/v trypsin-responsive microgels, 20% w/v PEG 
(non-enzymatically-degradable) microgels, or saline controls were delivered to the lungs 
of naïve mice via aerosolizer. The lungs were then excised at 0.5, 6, and 24 hours, and the 





the microgel decreased with time but was still visible at 6 hours after injection, 
representative images in Figure 20 and all IVIS images along with preliminary flow data 
in Figure 21. We expect that the levels of proteases present in the lungs were relatively low 
given that the mice were naïve, and thus the measured decrease in fluorescence should not 
be due to enzymatic degradation of the peptide backbone on the microgels, which was 
confirmed by the similar rates of clearance for both the enzymatically- and non-
enzymatically degradable Nano-in-Micro formulations. This suggests that without relevant 
proteases to degrade the microgels, they are most likely cleared by either macrophage 
phagocytosis or mucociliary clearance. 
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Figure 20: 20% w/v Trypsin- and PEG- Microgel Clearance in Naïve Mice (A) 
Representative IVIS Spectrum µCT images for background control (saline), trypsin-
responsive and non-enzymatically degradable PEG DyLight 650 labeled Nano-in-Micro 
particles at 0.5, 6, and 24 hours after instillation (n = 3 - 4). (B) DyLight 650 labeled Nano-
in-Micro fluorescence showing a similar decrease in measured radiant efficiency between 
both formulations over time. Kruskal-Wallis with Dunn’s multiple comparison test within 
each time point is not statistically significant, α < 0.01. 
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Figure 21: IVIS and Flow for 20% w/v CGRGGC and PEG Nano-in-Micro (A) All 
IVIS images for 20% Trypsin and 20% PEG microgel lung delivery, the lung from 0.5h 
trypsin with an ROI box was a sample injected into the esophagus and removed from the 
data sets (B) Preliminary flow data for Alveolar Macrophages and Neutrophils showing 
some uptake in individual mice but no group significance. 
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To determine whether the trends in macrophage phagocytosis in vitro were 
replicated in vivo, 20 and 30% w/v trypsin-responsive Nano-in-Micro particles were 
delivered via aerosolizer to naïve mouse lungs. Next, lungs were excised at 0.5, 6, and 24 
hours and imaged with IVIS. Similar trends of radiant efficiency were seen between the 20 
and 30% w/v formulations, Figure 22. Curiously, we observed the overall intensity of 
radiant efficiency was lower relative to Figure 20 (mean over 4x109 at 0.5 hours), which 
may have been due to delivery variability issues with the aerosolizer. However, clearance 
remained similar within formulations. Fluorescence for both clearance experiments, Figure 
20 and Figure 22, was maintained at 6 hours, showing that microgels for use with disease 
states should degrade within a short time frame (< 6 hours) for the nanoparticle cargo to be 
effectively released. Without a perceivable difference observed between the formulations 
a 20% w/v formulation may be all that is needed for the microgel to provide efficient, 
delivery within the short time frame in which the microgels can be degraded to release their 
nanoparticle cargo; this reduces the amount of polymer to fabricate the Nano-in-Microgels. 
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Figure 22: 20, 30% w/v Trypsin-Responsive Microgel Clearance in Naïve Mice (A) 
Representative IVIS Spectrum images for radiant background efficiency (untreated), 20 
and 30% w/v trypsin-responsive Nano-in-Micro particles at 0, 6, and 24 hours after 
treatment. (B) Measured radiant efficiency of delivered microgel fluorescence in the 
excised lungs. 
 Limited Phagocytosis in vivo Within 1 Hour of Administration  
To determine whether the microgels with different peptide crosslinkers were 
phagocytosed differently, a 1:1 ratio of trypsin-responsive microgels and elastase-
responsive microgels (labeled with DyLight 650 and DyLight 488, respectively) were 
loaded with Blue Fluospheres were delivered to the airways of mice. Microgels were 
administered with the aerosolizer (PC) or by oropharyngeal aspiration between Balb/c 
littermates. Additionally, microgels were delivered by oropharyngeal aspiration to 
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C57BL/6 mice from two age group (5-6 and 16-17-week old) since this strain is often used 
in LPS models of neutrophilic infiltration. One hour after delivery, and presumably after 
the elastase-responsive microgel would begin to degrade (Figure 12), the mice were 
sacrificed, the lungs collected, and digested into single cell suspensions. Stained samples 
were then run to determine the phagocytic cells positive for the different microgel 
formulations. Cell populations were defined as follows: 1) polymorphonuclear neutrophils 
(PMN): CD45+Ly6G+, 2) alveolar macrophages (AM): CD45+Ly6G-
SiglecF+CD11c+CD11b-, 3) eosinophils (Eo): CD45+Ly6G-SiglecF+CD11c-CD11b+, 
and 4) non-alveolar F4/80+ macrophages (Mφ): CD45+Ly6G-SiglecF-F4/80+. The 
MicroSprayer appears to deliver microgels within the target area near alveolar 
macrophages, Figure 19; however, the extent and dose with which these particles reach the 
lower airways may be low and with oropharyngeal aspirations may be lower still since the 
added velocity added by the MicroSprayer is absent. Additionally, the F4/80+ macrophage 
populations can include both non-alveolar macrophages as well as interstitial macrophages 
[176] that may or may not come in contact with the microgel formulations, skewing the 
percentages of populations positive for microgels low. Statistical analysis comparisons 
were within species for each cell type. 
The neutrophil populations for the MicroSprayer and oropharyngeal aspiration 
Balb/c delivery methods were significantly different and the alveolar macrophage 
population between the two C57BL/6 groups were significantly different using a two-way 
Anova (α = 0.01) with Sidak post hoc test, Figure 23A. While the microgel+ populations 
within each of the cell populations have median values below 5% for each type, (Figure 
23B-C), the elastase-responsive group has a few between 5-10%; the grey dashed line 
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marks the 1% threshold used to set the gates on FMOs. Due to the low number of cells 
within each of the sub-populations the nanoparticles (Figure 23D) were gated directly off 
their parent cell population rather than from the microgel positive populations with only 
the Balb/c F4/80+ macrophage populations showing cells positive for nanoparticles. 
Figure 23: Naïve Balb/c and C57/BL6 Uptake of Nano-in-Micro Particles (A) 
Neutrophil, eosinophil, alveolar macrophage, and F4/80+ macrophage populations for 
microgels delivered to Balb/c by aerosolizer (green), Balb/c by oropharyngeal aspiration 
(purple), 5-6-week-old C57BL/6 (light blue), and 16-17-week-old C57BL/6 (dark blue) 
mice by oropharyngeal aspiration; two-way Anova (α = 0.01) with Sidak post hoc. 
Percentage of neutrophils (PMN; CD45+Ly6G+), eosinophils (EO; CD45+Ly6G-
SiglecF+CD11c-CD11b+), alveolar macrophages (AM; CD45+Ly6G-
SiglecF+CD11c+CD11b-), and F4/80 macrophages (Mφ; CD45+Ly6G-SiglecF-F4/80+) 
positive for (B) trypsin-responsive microgels and (C) elastase-responsive microgels or (D) 
Blue Fluospheres; Mann-Whitney (α = 0.01). Grey dashed line marks the 1% threshold 
used to set the gates on FMOs. 
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While particle size is an important factor for phagocytosis and endocytosis, recent 
work looking at the relationship between particle elasticity and cellular uptake has shown 
that softer particles are often more difficult for cells to consume. This is because particle 
deformation leads to a greater extent of spreading between the elastic particle and the cell; 
specifically, phagocytosis by immune cells for particles in the softer (kPa) range have 
slower uptake than stiffer (MPa) particles [76,159,177]. We observed that with the 20% 
w/v trypsin- and elastase-responsive microgels, there was limited phagocytosis in the first 
hour by neutrophils, eosinophils, alveolar macrophages, and F4/80+ macrophages for both 
Balb/c and C57BL/6 mice regardless of delivery method (aerosolizer vs. oropharyngeal 
aspiration); we believe the combined size and softness of the microgels influenced this 
observation. 
Furthermore, the in vitro elastase-responsive microgels degraded in CF patient 
sputum within 30 minutes, Figure 12 and Figure 16, which suggested that the elastase-
responsive microgels should degrade and release nanoparticles before most of the 
microgels are cleared from diseased lungs. This microgel phagocytosis and clearance from 
Figure 19-Figure 23 was observed in naïve animals; however, under severe disease burdens 
(such as asthma, COPD, and CF) there is reduced phagocytic ability of these innate cells 
[178–181], which may create a longer window for the microgels to degrade—releasing 
their cargo. 
 Nano-in-Micro in an Acute LPS-Induced Lung Injury Model  
We tested the efficacy of the multi-stage particle system in an LPS-induced acute 
inflammation mouse model. Using microgels labeled with a near IR dye, DyLight 650, 
loaded with representative Blue (365/415) 100 nm Fluorosphere nanoparticles, the Nano-
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in-Micro were delivered intratracheally to mice treated with saline or LPS. The radiant 
efficiency in the excised lungs, corresponding to the fluorescence intensity of the microgel 
dye at 1, 6, and 22 hours after Nano-in-Micro delivery (3, 8, 24 hours post LPS), showed 
a significant reduction at 6 hour post Nano-in-Micro delivery, Figure 24A, revealing a 
faster microgel degradation in mice treated with LPS compared to the saline treated group.  
Concurrent with the observed microgel degradation, we observed reduced activation of 
blood PMNs over time (surface CD11b, Figure 24B), PMN recruitment to the airways with 
subsequent release of the neutrophil elastase (NE)-rich granules (surface CD63), and 
increased amount of the soluble neutrophil elastase in the bronchoalveolar lavage (BAL), 
Figure 24C-D. Together, these data suggest that the short-term clearance of the microgels 
during the LPS treatment is preceded by and dependent upon the degradation of the 
elastase-responsive peptides crosslinking the microgel. Notably, the subpopulation of LPS 
treated BAL PMNs double positive for both the Microgel and Nanoparticles showed 
increased surface CD63 expression, Figure 24E, suggesting that fusion to the plasma 
membrane of NE-rich granules and release of their content in the extracellular milieu is 
concomitant with increased uptake of soluble material. Lastly, analysis of the distribution 
of nanoparticles and microgel uptake by both, PMNs and macrophages, showed that airway 
PMNs, at 1 and 6 hour post-delivery, were primarily positive for nanoparticles alone, 
suggesting that our microgels were degraded, allowing the PMNs to access and endocytose 
the nanoparticles, Figure 24F. However, at 22 hours PMNs in the BAL and lung lysate 
showed equal uptake of both, the microgel and the nanoparticles, suggesting clearance of 
the remnant microresidues of the Nano-in-Micro system. As expected, BAL and lung lysate 
macrophages quickly began to phagocytose the Nano-in-Micro system. Notably, the 
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pattern of particle uptake by macrophages clearly differed from that of PMNs; the shift to 
nanoparticle alone at the later time-points may be due to either digestion of the microgels 
and subsequent intracellular release of the nanoparticles or to degradation of the dye 
labeling the microgels in the lower endosomal pH. 
Figure 24: Fluorescent Nano-in-Micro in an Acute Neutrophilic Inflammation Model 
(A) Representative IVIS images of excised mouse lungs with corresponding measures of 
radiant efficiency for 1, 6, and 22 hours (C) Increase in BAL elastase levels for the LPS 
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treated mice. (D) Increased CD63 expression on BAL PMNs and increased (E) CD63 
expression on Nano-in-Micro positive BAL PMNs (F) Percentage of BAL Neutrophils or 
Macrophages positive for nanoparticle only (black), Nano-in-Micro (blue), microgel only 
(dark grey), or negative for both (light grey). *p < 0.05, ** p < 0.01, *** p < 0.001 within 
time points indicated. 
 Delivering Therapeutics via Nano-in-Micro 
To determine whether the Nano-in-Micro system could not only effectively deliver 
nanoparticles to PMNs but also modulate inflammation, PLGA nanoparticles loaded with 
either Nexinhib20 and DiR (Nex20) or Tanshinone IIA and DiR (TIIA) were encapsulated 
into the 20% w/v elastase-responsive microgels. DiR is a near IR fluorescent dye, acting 
as a tracer for nanoparticle uptake, but upon release from the nanoparticle can potentially 
label the cell’s plasma membrane. Additionally, to assess if the particle formulation itself 
influenced the immune response, additional control groups for both saline and LPS treated 
mice were treated with a control DiR-only PLGA nanoparticles inside the elastase-
responsive microgel. The effects of the delivery of the therapeutics by the Nano-in-Micro 
system on systemic PMN responses were assessed in the blood (WB), bone marrow (BM), 
lung bronchioalveolar lavage fluid (BAL), and lung tissue lysate.  
While there was no detectable sign of neutrophilia or neutropenia in the blood 
relative to the saline control, the TIIA Nano-in-Micro treatment group did have statistically 
lower counts than the LPS treatment group and, while not statistically significant, the mean 
PMN TIIA count is 3-fold lower than the saline, Figure 25A. However, in the bone marrow, 
Nex20 and TIIA Nano-in-Micro treatment increased PMN bone marrow levels to those of 
the saline treated group, Figure 25B. Additionally, there appeared to be no therapeutic 
effects on the expression of inflammatory activation markers, Siglec-F and CD11b, for the 
LPS treated mice bone marrow PMNs, Figure 26.  
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Remarkably, unlike TIIA, delivery of Nex20 reduced the percentage and mean total 
number of PMNs in the lysate and BAL compared to the LPS treated control group, by 4.3- 
and 13-fold respectively, suggesting successful modulation of inflammation by delivery of 
the drug Nex20 to these PMNs by the Nano-in-Micro, Figure 25C-D. Neither the blood nor 
bone marrow PMNs were positive for the fluorescently labeled nanoparticle, DiR, Figure 
25E-F; however, confirming the Nex20 results, BAL and lysate PMNs treated with Nano-
in-Micro formulations were positive for the DiR dye suggesting endocytosis of the PLGA 
nanoparticles (control and therapeutic) by airway PMNs, Figure 25G-H. The modulation 
by Nex20 Nano-in-Micro seen in the bone marrow PMN counts together with the normal 
blood counts, point towards physiological feedback regulation of hematopoiesis and 
highlight the specificity of the delivery system in targeting only the desired organ and 
avoiding off-target systemic effects. 
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Figure 25: Nex20 and TIIA Nano-in-Micro PMN counts and DiR MFI (A) Blood PMN 
and (B) bone marrow PMN counts had no detectable signs of neutrophilia or neutropenia, 
while in the (C) lysate and (D) BAL the expected increase in PMNs with LPS treatment 
were abrogated in the Nex20 but not the TIIA treatment groups. As expected with site-
specific delivery, the DiR nanoparticle fluorescence was not picked up by PMNs in the (E) 
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blood or (F) bone marrow but was visible in the (G) lysate and (H) BAL. *p < 0.05, ** p 
< 0.01, *** p < 0.001, **** p < 0.0001 between groups indicated. 
 
Figure 26: Bone Marrow PMN SiglecF and CD11b Expression Increased expression of 
inflammatory markers (A) SiglecF and (B) CD11b on bone marrow PMNs in LPS treated 
groups. *p < 0.05 between groups indicated. 
To determine whether delivery of Nex20 and TIIA Nano-in-Micro could influence 
not only PMN numbers, but also their phenotype and function, active release of NE-rich 
granules was measured by flow cytometry on BAL PMNs. Most strikingly, concomitant 
with increased nanoparticle uptake by PMNs, Figure 25H, surface CD63 expression on 
BAL PMNs, reflective of NE release, was significantly lower for both therapeutic 
formulation than all other treatment groups, Figure 27A. Notably the Nex20 Nano-in-
Micro were also significantly lower than the saline treatment group. Blood PMN CD63 
expression for both therapeutic treatments appeared to have similar expressions as the 
saline group, Figure 27B. However, the lysate PMNs for TIIA had increased CD63 
expression—this subset also had increased SiglecF expression, Figure 27B-C. Despite 
similar PMN recruitment observed between the LPS alone and the control DiR PLGA 
Nano-in-Micro, the control N-in-M delivered to LPS treated mice activated the airway 
PMNs, resulting in a significant increase of both MMP9 and NE in the BAL, a respective 
 72 
2.7- and 28-fold increase relative to the saline treatment group, and a respective 1.3- and 
5-fold, compared to the LPS alone group. However, the delivery of Nex20 Nano-in-Micro 
abrogated this response with the levels of NE and MMP9 not significantly different from 
the saline control group. Unfortunately, this response was not observed for the TIIA which 
appears in line with the increased CD63 expression of the lysate PMNs. Additional tissue 
staining showed that delivery of Nex20 by the Nano-in-Micro system was able to reduce 
myeloperoxidase (MPO) positive cells, most likely PMNs, to the levels of the saline treated 
group; however, TIIA retained MPO activity. TIIA has previously been shown to modulate 
the proinflammatory immune response after injury for several mouse models (acute kidney 
injury, rheumatoid arthritis, LPS and smoke lung injury) by modulating the neutrophilic 
response, lowering MPO activity, and preventing epithelial damage from oxidative stress 
[182–184]; however, it has been shown to function in a dose dependent manner [182] and 
while the TIIA Nano-in-Micro appears to alter the LPS induced neutrophilic inflammation 
response the low encapsulation efficiency of TIIA in the PLGA may result in too low a 
dose to have effective reduction in inflammation.  
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Figure 27: Nex20, TIIA Nano-in-Micro BAL and Lysate PMN Phenotype Modulation 
(A) CD63 expression on BAL PMNs is significantly decreased for both Nex20 and TIIA 
treatment groups (B) Blood PMN CD63 expression appear to be decreasing (C) however, 
lysate CD63 expression is higher for the TIIA treatment group. (D) SiglecF expression of 
lysate PMNs is increased for both treatment groups. Nex20 Nano-in-Micro treatment is 
able to reduce the (E) soluble MMP9 and (F) soluble NE BAL levels. *p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001 between groups indicated.   
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Figure 28: MPO Tissue Staining Treatment with Nex20 Nano-in-Micro show decreased 
presence of myeloperoxidase (MPO) staining in tissue sections relative to the LPS and 
TIIA Nano-in-Micro treatment groups, scale bar = 20 µm, linearly contrasted for clarity. 
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As the TIIA Nano-in-Micro failed to reduce the soluble MMP9 and NE levels, it 
was removed from further BAL cytokine analysis. Surface elastase expression of 
extracellular vesicles has been shown to be integral to the PMN hyperexocytic 
inflammation process [185]. BAL extracellular vesicle surface elastase levels showed 
increased levels in the LPS and control Nano-in-Micro group which were lowered by 
Nex20 Nano-in-Micro treatment, Figure 29A. Nex20 Nano-in-Micro treatment was able to 
reduce important chemoattractant implicated in neutrophil and macrophage recruitment 
KC/GRO, IL-17A/F, and MIP-2, Figure 29B-D. Proinflammatory cytokines TNF, IL-6, 
and IL-1 were also reduced to within saline treatment levels, Figure 29E-G.Together, 
these results showcase the robustness of this novel delivery system, reflected by the 
successful delivery and preservation of the therapeutic efficacy of Nexinhib20.  
Here, we showed that the novel Nano-in-Micro delivery system, takes advantage 
of the highly proteolytic microenvironment to release nanoparticles to deliver 
immunomodulatory drugs to airway PMNs. Moreover, this shows that our N-in-M system 
allows for the delivery of drugs, such as Nexinhib20 that are only soluble in organic 
solvents such as ethanol and DMSO and as such limits their delivery to the lung. Here we 
have overcome this problem by compartmentalizing Nexinhib20 in nanoparticles allowing 
for pulmonary delivery to areas of highest PMN burden and protease activity. 
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Figure 29: Nex20 Nano-in-Micro Cytokine Analysis Treatment with Nex20 Nano-in-
Micro showed reduction of (A) EV-bound NE measured in the BAL. Proinflammatory 
cytokines (B) KC/GRO, (C) IL-17A/F, (D) MIP-2, (E) TNF (F) IL-6 and IL-1 were also 
low with Nex20 Nano-in-Micro treatment. *p < 0.05, ** p < 0.01, *** p < 0.001, between 




The purpose of these studies was to understand (1) the phagocytosis and clearance 
of the Nano-in-Micro system in naïve in vivo settings following pulmonary delivery and 
(2) test the efficacy of the delivery system in an acute neutrophilic inflammation mode. 
The trypsin peptide crosslinker was used to understand how the Nano-in-Micro system 
without specific enzymatic degradation cleared over 24 hours in vivo. We showed that the 
lowest starting polymer concentration to fabricate the Nano-in-Micro system (20% w/v) 
was not rapidly phagocytosed (< 1 hour) but sustained fluorescent signal at 6h. Using the 
elastase-responsive peptide, we showed during LPS-induced acute neutrophilic 
inflammation that specific targeting of airway cells was achievable with the presented 
Nano-in-Micro delivery system, which preserved the efficacy of the delivered drug. 
Moreover, this self-contained delivery method allowed the targeting of airway PMNs, 
making it a viable therapeutic strategy for PMN-driven inflammation in airway diseases, 
such as cystic fibrosis and chronic obstructive pulmonary disease.  
 In conclusion, the results of these studies show that the MADE method for 
fabricating multi-stage particles produces enzyme-responsive microgels, without exposure 
to degradative conditions to preserve therapeutic efficacy, and also allow for quick release 
of nanoparticles for targeting pulmonary disease. Future work in optimizing a dry powder 
formulation for existing pulmonary delivery devices (e.g., DPIs, nebulizers) is needed to 
translate the system into clinical usage. 
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CHAPTER 5. AIM 3: MICROPHSIOLOGIC VASCULARIZED 
LUNG-ON-A-CHIP 
Recent airway-on-a-chip microfluidic devices composed of a pseudostratified 
epithelium separated from a single layer endothelium by a synthetic polymer have allowed 
for simplified aspects of the lung environment to study the biochemical and metabolic 
activity in normal and diseased states [131–133]. However, replicating interstitial diseases 
such as iPF has been proven more difficult. Recently published methods have demonstrated 
that perfusable microvasculature can be recreated using microfluidics and that these in vitro 
techniques can reproduce normal and diseased states [107,186–188]. Improvements on the 
vascular design have created multi-layer microfluidic devices to observe the interactions 
between vasculogenesis and cancer organoids [189]. 
For most multilayered microfluidic devices, a semi-permeable cell culture 
membrane, often made of polydimethylsiloxane (PDMS) or polyester track-etched 
membranes, is used to create a physical barrier between cell types. These are significantly 
different from native extracellular matrix (ECM) and impact cell function and immune cell 
transport; however, thin films from native ECM have been incorporated into other multi-
layered microfluidic devices [190]. Additionally, the adjacent endothelial monolayer does 
not recreate the structures of pulmonary microvasculature and lacks relevant interstitial 
cells such as fibroblasts. The inclusion of fibroblasts in these co-cultures is important as 
cross-talk between fibroblasts and epithelium influences wound healing [191] and is 
particularly important in iPF where the epithelium has been shown to direct the fibrosis 
[18,192,193]. 
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Here, we show the design, fabrication, and cell troubleshooting of a multi-layer 
device to create the air-liquid interface of the upper respiratory airways that incorporates a 
vascularized endothelial network. We fabricated devices with both a 0.4 µm Polyester 
Track Etched (PETE) membrane and a more physiologically relevant vitrified collagen. 
Once the final design was chosen, microfluidic device fabrication was streamlined by 
formatting the microfluidic device into a 96 well format. A vitrified collagen membrane 
based microphysiologic device offered a physiologically relevant membrane that could 
allow for migration of immune-relevant cells into the apical side of the device. However, 
the natural-based fibrin gel used in the lower central channel for the vasculature began 
failing and had to be modified to create a stable hydrogel for use with the vitrified collagen. 
To show that the microphysiologic design was functional, 0.4 µm PETE devices were used 
to create a fibrosis-like pulmonary in vitro system.   
5.1 Methods 
 Individual Microphysiologic Device Fabrication 
Vasculature masters were fabricated on a silicon wafer by photolithography as 
previously described [187]. Slight modifications to the previously published designs were 
made and are detailed in Figure 30, courtesy of Michael Nelson. Airway masters were 
printed in Systems Accura 60 (Protolabs) with a 1 x 1 x 9 mm central channel and 1 mm 
guide marks matching the vascular microchannel layer ports. Devices were fabricated by 
bonding the feature side of the vasculature PDMS to the feature side of the (1 mm punched) 
airway PDMS with either a vitrified collagen membrane or a 0.4 PETE membrane (5.1.1.1 
and 5.1.1.2) sandwiched between the features. Media reservoirs were either fabricated by 
punching a 10:1 ratio elastomer to curing agent polydimethylsiloxane (PDMS, Sylgard 184 
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Dow Corning) block and bonding to the cured airway PDMS piece, Figure 30A, or by 
using a faster method (described below) which used a single airway-reservoir PDMS piece 
made by thermal bonding, Figure 30B.  
Figure 30: Vasculature Design Schematic (A) Overview of the 5-channel device with 
the media and gel ports labeled, (B) the 5 channels are each 1 mm wide and separated by 
(C) 50 µm ports designed to keep the air-liquid interface of the liquid fibrinogen and empty 
media channel as the fibrin gel forms.  
 
Figure 31: Single Device Fabrication Schematics (A) Three-piece or (B) two-piece 
fabrication sequence for the individual microphysiologic devices. 
To fabricate the airway-reservoir piece two methods were used, Figure 32. Media 
reservoir molds were fabricated out of EcoFlex (Smooth-On) or Smooth-Cast 310 
(Smooth-On). To fabricate the reservoir EcoFlex/Smooth-Cast mold a negative of the 
reservoirs was created by punching a 5:1 ratio of PDMS elastomer to curing agent with 4 
mm biopsy punches at the airway and vasculature media ports to match the full 3D printed 
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airway master. EcoFlex or Smooth-Cast 310 was poured over the negative following 
manufacturing instructions. The EcoFlex/Smooth-Cast mold was then briefly plasma 
treated (20 seconds) and silanized (trichloro(1H,1H,2H,2H-perfluorooctyl)silane) for more 
than 3 hours before pouring with PDMS. The airway and media ports were molded as one 
piece by pouring 10:1 PDMS in two stages: (i) the airway mold was poured with enough 
PDMS to slightly cover the ports and cured for 30-45 minutes at 65C (ii-EcoFlex) the 
without removing the cured PDMS, 2-3 mm of PDMS was poured on top of the cured 
PDMS, degassed and the EcoFlex mold was then aligned over the posts and cured at 65C 
for an hour. Alternatively, (ii-Smooth-Cast) the cured PDMS airway mold was removed 
from the master, the Smooth-Cast mold was then poured, degassed, the cured airway 
PDMS piece was then placed and weighted on the Smooth-Cast mold and cured at 65C 
for an hour. Once cured, the airway-reservoir PDMS layer was separated from the mold 
and punched with a1 mm biopsy punch.  
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Figure 32: Airway-Media Reservoir Fabrication Methods Single PDMS pieces of the 
airway mold and media reservoirs were fabricated by using either an EcoFlex or Smooth-
Cast mold and thermally bonding the PDMS as described in the schematic. 
5.1.1.1 Collagen Membrane  
A vitrified collagen membrane, to replicate the basement membrane, was made as 
previously described [190] directly on the punched airway channel by mixing rat tail type 
1 high concentrated collagen (Corning) with 10x PBS, 1N NaOH, DI water according to 
manufacturer's instructions for a final collagen concentration of 4 mg/mL. Once well 
mixed, approximately 35-40 µL of collagen was pipette across the open airway channel, 
incubated in a 37C humid incubator for 45-60 minutes, then allowed to dry at room 
temperature overnight. Membranes were then rinsed with DI water to remove excess salts, 
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water was aspirated, and membranes were allowed to dry for at least 6 hours before 
bonding. The vascular and airway layers were then treated with oxygen plasma for 60 
seconds using a Harrick Plasma Cleaner (PDC-001) and left to bake at 65C for at least 3h. 
Once fully bonded, excess PDMS was cut off the device sides. 
5.1.1.2 0.4 µm Polyester Trach Etched (PETE) Membranes 
PETE membranes were bonded with (3-aminopropyl)triethoxysilane (APTES) as 
previously described [194]. Briefly, optically transparent 0.4 µm PETE membranes were 
cut from 6-well Transwell (Corning), plasma treated for 20 seconds, and placed in 5% 
APTES preheated to 80C for 10 minutes. Membranes were then dried on a Kimwipe, the 
airway and vasculature PDMS surface was then activated with oxygen plasma and the 
membrane was sandwiched between the two PDMS pieces. This method also works with 
the Sterlitech PETE membranes; however, the 0.4 µm lack the optical transparency of the 
transwell membranes. 
 96-well Plate Microphysiologic Device Fabrication 
The vasculature microchannel design was adjusted so the media and gel ports 
centered in the middle of the 96-wells; new masters were fabricated by photolithography. 
As the silicon masters could only fit a 2 x 2 array, the vasculature master was poured twice 
for each 96-well plate. Airway masters were printed in Systems Accura 60 (Protolabs) with 
a 2 x 4 array of 1 x 1 x 14.57 mm central channel and 1 mm guide marks matching the 
vascular microchannel layer ports. PDMS molds of the airway channel were first bonded 
to black bottomless 96-well plates (Greiner Bio-One). 96-well bottomless plates were 
immersed in a 2% v/v solution of 3-mercaptopropyl timethoxysilane (Sigma Aldrich) 
diluted in methanol for 1 minute, rinsed with deionized water, and air dried. Plates and 
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PDMS airway molds were plasma treated, aligned, bonded together, and left at 65C 
overnight [195]. Collagen or PETE membranes were then added as described in sections 0 
and 5.1.1.2. The non-feature side of the vasculature molds was bonded to glass coverslips, 
then the feature side was aligned and bonded in pairs to the bottomless 96-well plate and 
airway channel, Figure 33A. Top view of the completed device can be seen in Figure 33B. 
Figure 33: 96-well Plate Microphysiologic Device Fabrication (A) 96-well fabrication 
plasma bonding sequence (B) Top view schematic of the 96-well design and cutouts of a 
single device PDMS layers. 
 Cell Culture and Device Seeding 
Normal Human Lung Fibroblasts (NHLF, Lonza lot # 608197 and # 508583) and 
Idiopathic Pulmonary Fibrosis Human Lung Fibroblasts (iPF-HLF, Lonza lot # 627840) 
were grown to passage 7 in Fibroblast Growth Medium-2 BulletKit (Lonza). Human 
Umbilical Vein Endothelial Cells (HUVECs, Cat # C2519A) were grown on 0.1% Bovine 
Gelatin (Sigma Aldrich) coated flasks up to passage 8 in Microvascular Endothelial Cell 
Growth Media-2 BulletKit (EGM2MV, Lonza). Normal Human Small Airway Epithelial 
Cells S-ALI Guaranteed (SAECs, Lonza lot # 677244) were grown in PneumaCult-Ex Plus 
to passage 3 and differentiated in PneumaCult-ALI medium (STEMCELL Technologies). 
Endothelial cells with or without iPF-HLF or NHLF (#608197) were resuspended in 
thrombin (4 U/mL) mixed 1:1 with fibrinogen/collagen (9 mg/mL / 1 mg/mL), unless the 
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gel was otherwise defined, and flowed into the lower central channel for a final 
concentration of ECs at 6e6 cells/mL and iPF-HLF at 0.3e6 cells/mL. NHLF (#508583) 
were resuspended in thrombin at 6e6 cells/mL (4 U/mL) mixed 1:1 with fibrinogen (10 
mg/mL) and flowed into the outer two side channels. The fibrin gels were then placed in a 
37C humid incubator to gel for 15 minutes before the addition of EGM2MV into the media 
reservoirs, media was then exchanged daily. On day 4 hSAECs were seeded in the top 
airway channel at 2.5e6 cells/mL in PneumaCult-Ex Plus, allowed to acclimate for 24 hours 
then airlifted by pipetting the media out of the upper channel. Once airlifted, a 50/50 
mixture of EGM2MV/PneumaCult-ALI was used to feed the device.  
 Fibroblast Screening 
Five lots of fibroblasts were purchased from Lonza (Lot #s: 580583, 608197, 
548315, 655309, 615568) and screened for their vasculogenic potential. Screening was 
completed in simple vasculogenic devices. Vascular masters were poured with 3-4 mm of 
10:1 PDMS and cured. Once cured the media ports were punched with a 4 mm biopsy 
punch and the gel ports were punched with a 1 mm biopsy punch. The feature side of the 
PDMS was then bonded to a square glass coverslip. HUVECs were seeded in the central 
channel to a final concentration of 6e6 cells/mL in a 3 mg/mL fibrin gel. Outer channels 
were seeded with each individual lot of fibroblasts (passage 7) at a final concentration of 
3e6 cells/mL in a final concentration 3 mg/mL fibrin gel. Devices were fed EGM2MV for 
5 days, perfused with dextran, then fixed and stained with phalloidin. 
 Fibrin-Collagen-PEG Hydrogels 
Fibrin, collagen, and PEG hydrogel combinations were loaded into the central 
channel of the vitrified collagen membrane devices. Fibrinogen was pegylated similarly to 
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previously published work [196,197]. Briefly, fibrinogen was dissolved at 12 mg/mL in 
PBS and sterile filtered. Immediately before use, 3400 Da bifunctional succinimidyl 
valerate (SVA) PEG (Laysan) was dissolved at 12 mg/mL and sterile filtered. Fibrinogen 
and PEG were mixed to twice the final concentration (PBS added to dilute as necessary), 
incubated the indicated amount of time at 37C and placed on ice before the addition of 
collagen. High concentration rat collagen was dissolved to 6 mg/mL following 
manufacturer’s instructions and left on ice.  
 Perfusion 
Device perfusion was imaged using a BioTek Lionheart system with a 4x objective. 
Montage parameters were set on each individual device, 50 µL of 10 µg/mL 70 kDa FITC-
dextran in PBS was added to one media port and the device was immediately imaged. 
Images were stitched and contrasted with Gen 5.04. For the percentage of perfusable area 
analysis the stitched images were straightened and cropped to remove the ports using 
Adobe Photoshop. Cropped images were then analyzed for fluorescent area using ImageJ 
by adjusting the threshold until all vessels were captured [198]. Images where the dextran 
leaked into the airway were excluded from analysis; images with perfusable vasculature 
with areas where the dextran flowed between the top of the gel and the bottom of the 
membrane had the area included in the calculation but not the GFP fluorescence.  
 Immunofluorescent Staining 
Devices were stained as previously described [186]. Briefly, devices were washed 
3 x with PBS, fixed with 4% paraformaldehyde for 10 minutes, permeabilized for 15 
minutes with 0.1% v/v Triton X-100, washed with PBS, and then blocked for 3 hours at 
room temperature with 5% w/v BSA and 4% v/v goat serum. Primary antibody was diluted 
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1:100 in the blocking buffer and devices were stained overnight at 4C. Devices were then 
washed with 0.1% w/v BSA in PBS. Devices were incubated with secondary antibodies 
diluted at 1:250 and DAPI diluted to 1:1000 in blocking buffer for 3 hours at room 
temperature; antibodies used are listed in Table 6. Devices were then washed in 0.1% BSA 
and imaged.  
Table 6: Antibodies Used for Microphysiologic Device Staining 
Target Clone Fluorophore Secondary 
⍺-SMA E184 Alexa Fluor 488 N/A 
TUBB4 6C2 Primary Goat-Anti Mouse 555 or 647 
Pro-Collagen I PCIDG10 Primary Goat-Anti Mouse 555 
CD31 WM59 Alexa Fluor 647 N/A 
Rabbit IgG Isotype EPR25A Alexa Fluor 488 N/A 
 
 Confocal Microscopy 
Fluorescent images were collected on a PerkinElmer UltraVIEW VoX spinning 
disk confocal microscope with a Hamamatsu C9100-23b back-thinned EM-CCD and 
Nikon 10x NA-0.3 air objective or a Nikon S Plan Fluor ELWD (extra-long working 
distance) 20x NA-0.45 air objective. To account for variability in the laser over time, 
devices for each experiment were imaged in a single session and devices from experimental 
groups were randomized during the session. Each device was imaged in 5-6 regions in the 
central channel, MFI was measured using Volocity software (Perkin Elmer) and if outliers 
were identified in GraphPad Prism by ROUT (Q = 0.2%) the entire device was removed 
from analysis. 
 Statistical Analysis 
Data were analyzed using GraphPad Prism with a Shapiro-Wilk test for normality 
(α=0.05). A one-way Anova (α = 0.05) with post-hoc Tukey’s test with an adjusted P value 
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for multiple comparisons, or a two-way Anova (α = 0.05) with Sidak post hoc analysis was 
used with parametric data. Where applicable, Kruskal-Wallis (α = 0.05) with Dunn’s test 
was used for nonparametric data 
5.2 Results  
 Microphysiologic Device Overview 
We designed a microphysiologic device to recapitulate the endothelial vasculature, 
stromal environment, and epithelial cell layers of the lower respiratory airways, Figure 
34A. It was composed of two main PDMS pieces; the bottom layer was a 5-channel device 
that provided the structure to create a vascularized hydrogel in the center of the device 
while the second layer provides a single channel for airway epithelium, Figure 34B. The 
vascular layer had 2 outer channels (green) for normal human lung fibroblasts (NHLF) that 
created a cytokine gradient for vasculogenesis of the central channel (purple) loaded with 
human umbilical vein endothelial cells (HUVECs) with or without human lung fibroblasts 
(HLF). This device also provided the media channels for the entire microphysiologic 
device (red). The airway was a second PDMS piece punched at each of the gel and media 
channels (color coded) with a single channel that sat above the HUVEC/HLF channel for 
small airway epithelial cell (SAECs) culture. A thin film membrane was placed between 
the two layers to allow for gel loading and a substrate for the epithelial cell growth and 
differentiation. The vasculature layer was seeded first, Figure 34C, followed by the 
epithelium on day 3, which was then airlifted the next day and allowed to differentiate for 
the following 5-7 days. We confirmed the HUVECs formed vessel structures (white arrow 
YZ section) within a fibrin gel below the airway epithelium (green arrow), Figure 35.  
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Figure 34: Microphysiologic Device Layout Schematics (A) Diagram of the lung 
physiology replicated (B) The device is composed of two PDMS layers separated by a thin 
film membrane, bonded together to create the multi-layer device. (C) Schematic of the 
microphysiologic device cross section and time course for cell growth and structure. 
Figure 35: Device Staining and Cross Section Microphysiologic devices (0.4 µm PETE) 
were stained for F-Actin (white) and tubulin IV (green). Extended Focus Z-stacks of the 
XY plane show F-Actin staining throughout the device, while tubulin appears in the 
epithelium, YZ sections show vascular structures (white arrow) below the epithelium 
(green arrow).  
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 Fibroblast Screening 
Initial devices were seeded with mesenchymal stem cells in the outer stromal cell 
channels, and while they formed vasculature, the ports failed to consistently open for 
functionally perfusable devices. Five lots of fibroblasts were tested for their ability to direct 
vasculogenesis. Lots were designated A-E, and donor information provided by Lonza 
certificates of analysis can be found in Table 7. While each fibroblast lot created-vessel 
like structures, only two lots created at least partially perfusable devices, Table 7 and 
Figure 36. 
 
Table 7: Fibroblast Lot Summary Information 





A 580583 79 F C Y 6/6 
B 608197 67 M C N 4/8 
C 548315 52 M C Y 3/6 
D 655309 56 M B N 0/7 
E 615568 12 M H N 6/6 
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Figure 36: Fibroblast Lot Effects on HUVEC Vasculogenesis and Perfusion 
Representative images of perfusable vasculature alongside the same fixed F-Actin stained 
devices for passage 7 fibroblasts.  
These two lots were then seeded into the vitrified collagen microphysiologic 
devices in the outer channels with and without the respective lot also seeded at a 10:1 
HUVEC to NHFL ratio in the central channel for 12 days. Devices seeded with lot E 
(615568) fibroblasts had begun to overgrow resulting in large flat regions of FITC-Dextran 
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signal due to leakage rather than perfusion, Figure 37. Lot A fibroblasts created perfusable 
networks with endothelial only devices; however, with endothelial/fibroblast co-cultures 
the devices began to overgrow as well. Lot A (580583) was chosen for the outer channels 
to direct vasculogenesis while lot B (608197) was chosen for future co-culture with 
endothelial cells in the central channel. Lot B was chosen for the central channels since it 
appeared to form some vasculature suggesting it provided necessary cytokine signaling but 
was not as effective as A, so we believed that the lot A fibroblasts could produce a 
competitive cytokine gradient relative to B to create vasculature with fibroblasts.  
Figure 37: Fibroblast Lot Effects on Microphysiologic Lung-on-a-Chip Vasculature 
70 kDa FITC-Dextran perfusion of 12 day cultured vitrified collagen microphysiologic 
devices loaded with the two perfusable fibroblast lots in the outer channels and HUVECs 
with or without the respective fibroblast lot at a 1:10 ratio in the central channel, and 
hSAECs in the airway channel.   
 Fibrin/Collagen Hydrogels  
To further improve the vascular network, collagen was added to the fibrin gel since 
fibrin/collagen hydrogels of various ratios have been shown to improve tubule formation 
[104,199]. The total gel concentration was kept at 5 mg/mL, and collagen was added from 
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0.25-1 mg/mL. Devices were seeded with a 20:1 HUVEC to NHLF in vitrified collagen 
and PETE membrane devices. Oddly, all vitrified collagen devices including the fibrin only 
gel that had previously been successful began failing on day 4. The gel pulled off the posts 
on day 4 and eventually collapsed the rest of central channel, Figure 38. The PETE based 
microphysiologic devices did not have this issue, and, based on phase contrast imaging, 
the 4.5/0.5 mg/mL fibrin/collagen gel was chosen for future studies, Figure 39.  
Figure 38: Vitrified Collagen Device Fibrin/Collagen Hydrogel Failure HUVECs and 
NHLFs (20:1) were seeded in fibrin/collagen gels at final concentrations of 4/1, 4.5/0.5, 
4.75/0.25, and 5/0 mg/mL (n = 8 per gel). Phase contrast images of representative devices 
for each gel type were taken on day 2 and 4 after seeding. White arrows indicate regions 
where hydrogel failure can be seen, yellow arrows point to the visible lack of gel in a post 
between the two time points, scale bars = 1000 µm.  
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Figure 39: PETE Device Fibrin/Collagen Hydrogels HUVECs and NHLFs (20:1) were 
seeded in fibrin/collagen gels at final concentrations of 4/1, 4.5/0.5, and 5/0 mg/mL. Phase 
contrast images of representative devices for each gel type were taken on day 2 and 4 after 
seeding, scale bar = 1000 µm. 
Since the human fibrin only gel formulation had been previously successful, the 
vitrified collagen devices were loaded again with 5 mg/mL fibrin gels but exhibited similar 
results with 35 of 40 devices failing (~12.5% success rate). Since the hydrogel failures 
were not observed with the stiffer PETE membranes, failure in the vitrified collagen 
devices was most likely a result of the forces exerted on the hydrogel by the HUVECs and 
NHLFs in combination with the flexibility of the vitrified collagen membrane.  
 Fibrin/Collagen/PEG Hydrogels for Vitrified Collagen Devices 
The loss of a stable fibrin hydrogel may be due to batch-to-batch variability of the 
human fibrinogen; this poses a significant problem for disease-relevant devices as fibrotic 
myofibroblasts, are contractile cells [200–202]. PEG has been previously used to create a 
stiffer fibrin hydrogel with 5 mg/mL Fibrin and 0.5 mg/mL bifunctional succinimidyl 
glutarate (SG) PEG [196,197]. Here we modified the fibrinogen with a bifunctional 
succinimidyl valerate (SVA) PEG. PEG-SVA was chosen over PEG-SG as SVA has a 
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reactivity half-life of approximately 30 minutes, double the time for SG. Various 
combinations of fibrinogen, collagen, and PEG with varying preincubation times for the 
fibrinogen with the PEG were tested for gelation times within 15 minutes, Table 8, gel 
combinations that did not gel are labelled DNG. Of note the previously published ratios of 
fibrin/peg 5/0.5 mg/mL did not gel with preincubation for PEG-SVA; however, lower 
concentrations of PEG resulted in stable hydrogels.  Hydrogel combinations that gelled 
within 15 minutes were tested in vitrified collagen devices. 
 
Table 8: Fibrin/Collagen/Peg Hydrogel Formulations Tested 
Fibrin Collagen SVA-PEG-SVA  
 
(mg/mL) (mg/mL) (mg/mL) Pre-incubation (min)  Experiment End 
5 0 0 N/A Day 4 
5 0 0.5 0 Day 5 
5 0 1 15 DNG 
5 0 0.5 15 DNG 
5 0 0.5 30 DNG 
5 0 0.25 30 >Day 9 
5 0 0.1 30 >Day 9 
4.75 0.25 0 N/A Day 4 
4.75 0.25 0.25 0 Day 5 
4.75 0.25 0.5 15 DNG 
4.75 0.5 0.25 15 >Day 5 
4.75 0.25 0.25 15 >Day 5 
4.5 0.5 0 N/A Day 4 
4.5 0.5 0.1 N/A >Day 8 
4.5 0.5 0.25 15 >Day 8 
4.5 0.5 0.5 15 Day 1 
4 1 0 N/A Day 4 
4 0 1 15 DNG 
4 0.5 1 15 DNG 
5 (Bovine) 0 0 N/A >Day 8 
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Four combinations of fibrin/collagen/PEG (5/0/0.1, 5/0/0.25, 4.5/0.5/0.1, 
4.5/0.1/0.25) survived 8-9 days of HUVEC/NHLF (20:1, VEGF/Ang-1) culture without 
signs of hydrogel failure, representative images Figure 40A. Perfusion in the devices was 
quantified with 70kDa FITC-dextran by the percentage of GFP positive area, Figure 38B, 
and percentage of perfusable ports, Figure 40C. Vasculature only devices published by 
Kim et al. had vessel area between 60-80% [187], this range is represented by grey dashed 
lines, Figure 38B. Alongside the 4 human fibrin combinations, 5 mg/mL bovine fibrin gels 
were tested. Of the 5 hydrogel formulations, the two human-fibrin/PEG formulations 
without collagen had the highest number of devices (4/7 and 6/7) within the 60-80% 
perfusion range. The bovine fibrinogen had 75% of the devices with 100% open 
(perfusable) ports; however, the HUVEC/NHLFs structured into large overgrown vessels 
rather than microvasculature. It is possible that the seeding density of HUVECs could be 
titrated to find a more-optimal density for the long culture times. 
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Figure 40: Fibrin/Collagen/PEG Vitrified Collagen Microvascularized Lung-on-a-
Chip  (A) Representative images of 70kDa FITC-Dextran perfusion in vitrified collagen 
devices, scale bar 500 µm. (B) Percentage of the central channel area between the posts 
positive for the 70kDa FITC-Dextran (GFP+). (C) The percentage of ports imaged that had 
perfusable vasculature. 
 0.4 µm PETE Fibrosis Model 
Microphysiologic devices fabricated with 0.4 µm PETE membranes were seeded 
with either NHLF or iPF-HLF in the central channel alongside HUVEC in a 4.5 mg/mL 
0.5 mg/mL Fibrin/Collagen hydrogel, maintained for 5 days and then treated with or 
without 5 ng/mL of TGF-1 for 3 more days. TGF-1 is often overexpressed by 
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myofibroblasts in iPF and is known to help progress fibrosis [191,202]. Hallmarks of 
myofibroblasts and resulting fibrosis include pro-collagen 1 and -smooth muscle actin 
(-SMA). Microphysiologic devices with NHLF and iPF-HLF stained positive for -SMA 
with and without the TGF-1 treatment, Figure 41B. Each device stained positive for pro-
collagen 1, possibly caused by non-specific binding of the antibody to the fibrin/collagen 
hydrogel mixture used for the devices. As the perfusable endothelial networks were still 
inconsistent in these devices, media was supplemented with VEGF and Ang-1 for the first 
4 days of culture in subsequent experiments. 
 
 99 
Figure 41: NHLF and iPF Device Pro-Collagen I and -SMA Staining 0.4 µm PETE 
microvascularized lung-on-a-chip devices seeded with either NHLF or iPF-HLF alongside 
HUVECs in the central channel treated with or without 5 ng/mL of TGF1. Devices were 
stained for vascular endothelium (CD31, red), pro-collagen 1 (yellow), -SMA (green), 




 0.4 µm PETE Devices Treated with Pirfenidone 
Pirfenidone is an antifibrotic drug used for treating iPF that often reduces the 
expression of -SMA in vitro cultures of fibroblasts [202]. Microvasculature lung-on-a-
chip devices were seeded with healthy fibroblasts, Figure 42A, or iPF fibroblasts alongside 
the HUVECs in the central channel. After 8 days of culture, (D5 of ALI), devices were 
seeded with media containing 50 or 100 µg/mL of Pirfenidone and on day 9 the cultures 
were ended and devices were perfused, representative images Figure 42B, then fixed and 
stained for -SMA, endothelial cells (CD31), and nuclei (DAPI), representative images 
Figure 42C. The devices with NHLF had too much variability in perfusion measured by 
the percentage of open ports and the perfusable area to see changes in the Pirfenidone 
treatment, Figure 42D. For the devices with iPF derived fibroblasts, there appeared to be 
variability in perfusion of the devices with the increase in pirfenidone treatment negatively 
affect the percentage of perfusable vasculature across the device; however, there was no 
statistical significance, Figure 42E. Additionally, there was no change in the expression of 
-SMA for either NHLF or iPF devices and notably no apparent difference in -SMA MFI 
between the healthy and diseased fibroblasts. It is possible that while these fibroblasts had 
some base-line expression of -SMA (relative to isotype control) that the fibroblasts alone 
are not able to recapitulate the fibrotic environment and additional treatment to the devices 
may be needed to induce fibrosis. 
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Figure 42: Pirfenidone Treated NHLF and iPF Microphysiologic Devices Devices 
were seeded with NHLF or iPF fibroblasts and treated with 50 or 100 µg/mL Pirfenidone 
on Day 8 (A) Representative extended focus z-stack of nuclei (DAPI) and endothelial cells 
(CD31) and XY, XZ, and YZ views of the endothelial tubules; images linearly contrasted 
for clarity, scale bars = 70 µm. (B) Representative images of 70kDa FITC-Dextran 
perfusion, scale bar = 500 µm. (C) Representative images of fibroblast -SMA (green), 
endothelial cells (CD31-red) and nuclei (DAPI-white), linearly contrasted for clarity, scale 
bars = 50 µm. Characterization of vasculature by percentage of open ports for each device, 
percentage of the central channel area between the posts positive for the 70kDa FITC-
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Dextran (GFP+) and -SMA mean fluorescence intensity (MFI) for (D) NHLF and (E) iPF 
microphysiologic devices. Bars indicate statistical significance,  = 0.05. 
Next, microvascularized lung-on-a-chip devices were treated with or without 5 
ng/mL of TGF-1 for 3 days (D5 of culture D1 of ALI) to push the fibroblasts toward a 
myofibroblast phenotype. The devices were then treated with 50 or 100 µg/mL of 
Pirfenidone for 24 hours. Perfusion of the devices, representative images Figure 43A, 
showed the addition of TGF-1 to the normal fibroblast cultures did not appear to impact 
vessel quality based on the number of perfusable ports and the percentage of perfusable 
area, Figure 43B-C. In the NHLF devices the addition of pirfenidone to the TGF-1 in the 
normal fibroblast devices appeared to cause the vasculature to become less stable as 
devices had fewer open ports and less perfusable area. Within this experiment the iPF 
seeded microphysiologic devices without any treatment had less than 60% perfusable area 
while the NHLF based devices were at 60-80%. The iPF devices also appeared to be 
sensitive to the TGF-1 treatment as the perfusable area appeared to drop and increased 
with the 100 µg/mL pirfenidone treatment, Figure 43B-C; however, there is no statistical 
significance. Staining for -SMA, representative images Figure 44A, did not show 
increased MFI in the TGF-1 groups for either NHLF or IPF, Figure 44B-C. However, the 
NHLF TGF-1 was lower than the untreated devices and 50 µg/mL Pirfenidone but not the 
TGF-1 only treatment. It is possible that the current imaging technique is not sensitive 
enough to detect appreciable changes to the -SMA in these microphysiologic devices. 
Future experiments to increase the -SMA may be necessary to show an effective fibrosis 
model; TGF-1 concentrations can be increased or bleomycin injury to the epithelium may 
be tested to see if the fibroblasts can be pushed to a more myofibroblast phenotype. 
 103 
Figure 43: TGF-1 and Pirfenidone Treated NHLF and iPF Devices 
Microvascularized lung-on-a-chip devices seeded with normal and iPF fibroblasts were 
treated with/without 5 ng/mL TGF-1 for 3 days and with 50 or 100 µg/mL Pirfenidone 
for 1 day (A) Representative images of 70kDa FITC-Dextran perfusion, scale bar = 500 
µm. (B) Percentage of open ports for each device and (C) Percentage of the central channel 
area between the posts positive for the 70kDa FITC-Dextran (GFP+).  
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Figure 44: -SMA Staining and Quantification Microphysiologic devices seeded with 
either normal or iPF fibroblasts alongside HUVECs were treated with 5 ng/mL of TGF-
1 for 3 days and Pirfenidone for 1 day. (A) Representative fluorescent images of nuclei 
(DAPI-white), fibroblasts -SMA (green), endothelial cells (CD31-red), linearly 
contrasted for clarity, scale bars = 50 µm. -SMA mean fluorescent intensity for (B) NHLF 
and (C) iPF microphysiologic devices. Bars indicate statistical significance  = 0.05. 
5.3 Conclusions 
We have successfully fabricated a multi-layer microphysiologic device that allows 
for the co-culture of endothelial cells in a vascular network alongside healthy or diseased 
fibroblasts below an airway epithelial layer. Devices were fabricated in a 96-well format 
for easier handling and medium-throughput experiments. Vitrified collagen membranes 
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could be incorporated into the microvascularized lung-on-a-chip with the addition of PEG 
into the fibrin hydrogel structure. Future analysis of the vasculature structure with 
Angiotool may be necessary to determine the vessel quality.  
0.4 µm PETE membrane-based devices were able to recapitulate microvasculature 
with healthy and diseased iPF fibroblasts within the fibrin interstitium-like hydrogel. 
Increased -SMA staining was visible in preliminary fibroblast-HUVEC co-cultures and 
treatment with anti-fibrotic Pirfenidone in TGF-1 fibrosis appeared to rescue the 
microvascular structure. Effects of the Pirfenidone on the fibroblast expression of -SMA, 
MMP production or other inflammatory cytokines released have yet to be elucidated and 




CHAPTER 6. CONCLUSIONS AND FUTURE WORK 
In this dissertation the overall objective was to study the Nano-in-Micro multi-stage 
particles by investigating (i) how the microgels and nanoparticles interact with the 
phagocytic immune cells in vitro (Aim 1) and in vivo (Aim 2) and (ii) how we can 
recapitulate the vascular pulmonary environment to study these interactions in an in vitro 
setting (Aim 3) 
 Nano-in-Micro System 
Nano-in-Micro multi-stage particles were studied to (i) provide aerodynamic size 
(ii) avoid rapid macrophage phagocytosis and (iii) deliver fluorescent and therapeutic 
nanoparticles for efficient endocytosis. Despite extensive knowledge on particle deposition 
and transport in the airways, there are several innovative aspects derived from this current 
work. This in vitro work has further improved upon the MADE method by changing the 
chemistry for faster reaction kinetics, shown the incorporation of a disease-relevant 
protease-responsive peptide, and shown the flexibility in exchanging nanoparticles 
between fluorescent polystyrene beads and drug-loaded PLGA nanoparticles. The 
successful deposition and efficient delivery of nanoparticles to neutrophils in immune 
mediated diseases to the deep lung which avoid rapid clearance will facilitate development 
of the next generation of highly effective pulmonary drugs. 
The in vivo work showed the lowest starting polymer concentration to fabricate the 
Nano-in-Micro system (20% w/v) was not rapidly phagocytosed but sustained fluorescent 
signal, lowering the amount of polymer needed for fabrication. Further improvements to 
the manufacturing method could include high throughput production of single emulsion 
particles with appropriate size. Potential alternatives could include microfluidic based 
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arrays that can be designed to process larger volumetric scales [203]. Additionally, here 
we showed the rapid degradation of the microgels using a single protease-responsive 
peptide. Different molar ratios of peptide to PEG, or percentage of degradable peptide 
incorporated into the backbone could be used to adjust the degradation time of the 
microgels to create a time-dependent release of the nanoparticles. Furthermore, a 10kDa 4-
arm PEG maleimide was used in this work. If the molecular weight of the PEG backbone 
were increased this could increase the swelling ratio and resultant swollen size of the 
microgels potentially increasing the residence time of the microgels before phagocytosis.  
We showed this multi-stage formulation allowed for the targeting of airway PMNs 
in an acute neutrophilic inflammation model, effectively delivering the immunomodulator 
Nexinhib20 to reduce the inflammatory cytokines released by the inflammatory 
neutrophils. Alternative nanoparticle formulations could also increase the loading 
efficiency of Nexinhib20 into the nanoparticle, which could then be used to adjust the 
therapeutic dose delivered by the nanoparticles. Roscovitine encapsulated into the PLGA 
nanoparticles with high efficiency in vitro and as a potent inducer of neutrophilic apoptosis 
would be an excellent alternative to test for therapeutic efficacy in place of Nexinhib20. 
Future work in chronic neutrophilic inflammation models such PGP induced inflammation 
would be necessary to confirm this multi-stage system is a viable therapeutic strategy for 
chronic airway diseases, such as CF and COPD.  
The Nano-in-Microgels used throughout this work were delivered in their swollen 
state. For translation to a clinical system, a dry powder formulation with appropriate 
excipients such as lactose, mannitol, or trehalose would need to be developed and tested. 
Preliminary testing of excipients with microgels revealed that after lyophilization a T2 
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Turbula Blender would be necessary to create a free-flowing powder that could then be 
tested for aerodynamic properties with a next generation impactor. Larger batch processing 
of the Nano-in-Micro particles would also be necessary to fill capsules used with current 
existing pulmonary delivery devices (e.g., DPIs, nebulizers).  
 Vascularized Lung-on-a-Chip 
We have shown a novel approach to developing a microvascularized lung-on-a-
chip. Numerous approaches for developing either an air-liquid interface for airway 
epithelium or vascular networks in vitro have been developed. These devices have allowed 
for different pieces of the lung environment to be studied in vitro in normal and diseased 
states. This lung-on-a-chip that we have developed is unique since it brings together a few 
of these separate pieces; the lower gel allows for a 3-dimensional vasculature network to 
form. This endothelial space also allows for relevant stromal cells e.g., healthy or diseased 
fibroblasts, to be incorporated into the microfluidic device in a physiologically relevant 
structure—around the vasculature and below the airway epithelium. Additionally, as will 
be discussed later in this section, multiple different disease-like models can potentially be 
fabricated by exchanging the cells of interest.  
The fabrication of microfluidic devices was improved by transitioning from 
individual microfluidic devices to a 96-well format. This increased the ease of fabrication 
as well as the quantity of devices that could be fabricated in a single batch. Additionally, 
this allowed the number of devices seeded per experiment to increase, increasing both the 
number of groups and higher n within each experiment. With less handling of each 
individual device and an increase in the rigidity of the plate structure there were overall 
fewer device failures over the 1-2-week cultures resulting from handling the flexible 
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PDMS devices (e.g., accidental bending/stretching leading to leaking in the airway 
channel). Further improvements to device loading such as consistent accurate cell counts, 
titrating the seeding density of endothelial cells for 2-3-week cultures to prevent 
overgrowth in the lower hydrogel channel. 
However, there is still characterization that needs to be completed. Cytokine 
analysis of the normal devices relative to the diseased, TGF1 induced or iPF, would be 
worth studying to show if biomarkers observed in patients were replicated. Further 
microscopy characterization is necessary especially with the airway epithelium. We have 
shown preliminary tubulin IV staining that indicates cilia-like structures; however, without 
higher magnification imaging we have yet to determine if functional cilia form. This is 
necessary since these devices have not been cultured for two-week or longer cultures of 
ALI which is usually when fully differentiated cilia present. Furthermore, airway 
epithelium is a heterogeneous population and other stains such as tight junction (Z01), 
MUC5AC or MUC1, and club cells (uteroglobin) would be useful to our understanding the 
epithelial structure formation as well as the mucosal structure created in the co-cultured 
system. The vertical structure of these microfluidic devices is an inherent limitation for 
microscopy. To image in the z-plane requires objectives with 2-4 mm working distance 
which usually results in a lower NA. This reduces the resolution and increases depth of 
focus allowing more out of focus light, limiting the fine resolution imaging of intracellular 
structures. 
Most vasculature microfluidic devices rely on the use of HUVECs. Future work 
moving away from HUVECs to lung-derived endothelial cells may be necessary when 
studying the cross-talk between epithelium and endothelium during wound repair and 
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fibrosis specific to iPF, acute lung injury, or COPD. However, similar to the fibroblast 
screen completed, screening microvasculature endothelial cells would be necessary to 
ensure that tubule formation occurs. Although a patient-derived microfluidic device for the 
testing of patient-specific response to therapies would be an ultimate target, ensuring that 
the troubleshooting presented in this work (fibroblast, hydrogel, or media screening) would 
not be necessary would require a more consistent hydrogel formulation that can promote 
vasculogenesis even with endothelial lots that resist vasculogenesis. 
The vitrified collagen membranes have only been tested at a final 4 mg/mL 
concentration. Varying the concentration as well as the volume of the collagen used to 
create the membranes on the microphysiologic devices could adjust the thickness and 
quality of the membrane. Additionally, other ECM based thin film membranes including 
alginate and Matrigel could be used to improve this physiologically relevant membrane 
thus reducing the number of devices that lose the ability to maintain the air-liquid interface 
and promote better differentiation of the epithelial layer. 
The current hydrogel is primarily a naturally-derived fibrin network which has lot-
to-lot variability. This inconsistency has proven detrimental to the vitrified-collagen 
devices. Transitioning to a purely synthetic hydrogel would be beneficial to prevent such 
lot-to-lot variability as well as control the composition and signaling that the cells receive 
by the addition of bioactive motifs. A PEG based hydrogel may be worth investigating 
since a high degree of commercially available chemical modifications, molecular weights, 
and multi-arm products exists allowing for easy incorporation of bioactive peptide 
sequences as well as tethering potentially necessary angiogenic cytokines such as VEGF. 
The hydrogel at minimum would require the incorporation of degradable peptides for the 
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endothelium to restructure the network as well as adhesion motifs such as GRGDSPC. 
Additionally, for use with vitrified collagen membranes the mechanical properties can be 
tailored with more control.  
Although Michael-addition type reactions have been presented throughout this 
work, the time constraint of the quick maleimide-thiol kinetics would make loading the 
microfluidic devices difficult, and an acrylate-thiol reaction would be too slow resulting in 
cells settling during gelation. A light-mediated thiol-ene hydrogel formulation would 
provide (i) controlled loading to gelation time, (ii) halved cell concentrations (hydrogel, 
crosslinkers, and cells in one vial) which would in turn also lead to (iii) reduced inter-
device inconsistencies caused by mixing the cells/thrombin with the fibrinogen and also 
potentially lowering cell counting errors.  
UV light-mediated systems rely on potentially cytotoxic co-initiators and 
monomers as well as subjecting the cells to potential damage from the light source itself. 
A preferred system is the visible light-mediated thiol-ene reaction with Eosin-Y as the 
initiator. Preliminary testing of a 4 and 6% w/v 10 kDa 4-arm PEG-norbornene (PEG-NB) 
with the RGD peptide and VPM degradable peptide (gift from the García lab) crosslinked 
via visible-light by Eosin-Y were successfully gelled in 30 seconds without cells in the 
individual microfluidic devices. However, the large swelling ratio of the PEG hydrogel 
caused the ports to bulge out into the media channels which may or may not be detrimental 
to the cells and vascular formation of the device. Lower molecular weight and higher armed 
PEG could potentially be tested to reduce the swelling ratios. Additionally, adjusting the 
percentage of the hydrogel that degrades, potentially designing alternative peptides that are 
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not as acidic, and titrating the concentration of the RGD adhesive peptide would be 
necessary to titrate to control the vasculature tubule formation. 
Finally, there are several disease-like models that can be tested in the current state 
of the microphysiologic devices. For the vitrified collagen devices, the 5/0.1 Fibrin/PEG 
hydrogel could be used to replicate neutrophilic inflammation; the SAECs in the air-lifted 
airways could be treated with or without inflammatory small molecules such as LPS or 
LTB4, and neutrophils could be introduced in the vascular portion of the device. 
Exchanging the hSAECs for CF-derived patient airway epithelial cells would also allow 
for the creation of a CF-like microphysiologic device that could also be expanded to test 
neutrophilic transmigration. 
For the 0.4 µm PETE based microphysiologic devices, basal to apical 
transmigration is not possible with the pore size and the few 10 µm pore sized devices 
tested would not hold the air-liquid interface. However, this microphysiologic device can 
be used for testing small molecule therapeutics and potential nanoparticle delivery to the 
apical side of the airway. Preliminary testing of hSAECs with A549s at a 1:40 ratio in the 
airways showed we could co-culture the adenocarcinoma cell line with the healthy cells 
for 5 days at ALI, small chemotherapeutics delivery routes media vs airways could be 
tested. Additionally, the fibrotic model presented in Chapter 5 can be characterized for 
fibroblast expression of -SMA, MMP production or other inflammatory cytokines 
released to determine the extent of fibrosis recapitulated. 
This dissertation has investigated a multi-stage system for the delivery of 
therapeutics to respiratory airways and developed a microphysiologic device to recapitulate 
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